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The scientist does not study nature because it is useful to do so. He studies it because he
takes pleasure in it, and he takes pleasure in it because it is beautiful. If nature were not
beautiful it would not be worth knowing, and life would not be worth living.
Henri Poincaré, Science and Method (1908)
To my dear family.
POPULAR SCIENCE SUMMARY OF THE THESIS
For their actions, growth and programmed death, human cells need energy that can be stored
and distributed via the energy­richmolecule ATP. A large proportion of ATP is produced in the
cellular organelle mitochondria, which are central platforms for converting metabolites into
building blocks for cells. Their malfunction can have detrimental effects on human health.
Inborn mitochondrial disease affects at least 1 in 5,000 individuals and causes a wide range
of clinical symptoms. However, it is poorly understood how defective mitochondria cause
disease on the level of cells and the whole body. A new set of omics methods and powerful
computers now enable the measurement of thousands of molecules at the same time. In this
thesis, I explore the use of omics tools in combination with genetic models of human disease
in order to capture the systemic biological consequences of mitochondrial malfunction.
Electron microscopy picture of fruit fly mitochondria,
healthy (left) and sick (right).
I shed light on small protein modifica­
tions in mitochondria, which are known to
regulate protein function and stability. I map
the smallest chemical modification called
methylation on mitochondrial proteins, and I
pinpoint processes that depend on methyla­
tion. By modeling patient­specific fruit flies
I demonstrate that a simple dietary increase
of the amino acid methionine was beneficial
for the diseased flies. Moreover, I develop a method called ”SILAF” to identify novel proteins
that are modified by phosphorylation and that are relevant to human disease. Furthermore, I
make use of omics tools on human neuronal stem cells to find the cause for brain defects in
patients with inborn errors of metabolism. Lastly, I monitor how mitochondria signal stress
to the rest of the cell through leakage of RNA components in fly models.
These studies give insight into a novel layer of complexity in the cell, which is far from
completely mapped and understood. Importantly, the translational perspective provides thera­
peutic avenues for patients with mitochondrial malfunction, which is also relevant to diseases
with disturbed metabolism during ageing and in cancer.
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SVENSK SAMMANFATTNING
Mänskliga celler behöver energi för att växa och genomföra deras specifika funktioner. ATP
är en energirik molekyl som behövs i många cellulära reaktioner och som framförallt bildas i
mitokondrierna. Dessa cellorganeller är centrala för ämnesomsättningen av molekylära byg­
gstenar och nedsatt mitokondriefunktion kan leda till sjukdomar. Ungefär en av 5000 män­
niskor riskerar att utveckla mitokondriell sjukdom, som är en grupp av sjukdomar med en
mycket varierad klinisk bild. Detta forskningsarbete behandlar frågan om hur dessa sjukdo­
mar uppstår på cellnivå. En ny generation av metoder som kallas ”omics” kan nu användas för
att mäta tusentals molekyler samtidigt. Jag använde dessametoder tillsammansmed genetiska
modeller som bananflugor, möss och humana celler för att förstå systemiska konsekvenser av
mitokondriella sjukdomar. Studierna visar på ett nytt sätt hur komplex regleringen av celler­
nas funktion är utöver den som sker på proteinnivå. Dessutom bidrar denna translationella
forskning till nya terapikoncept för patienter med medfödd mitokondriell nedsättning och
utökar vår förståelse för bristfälliga metabola processer i cancer och i den normala åldrande­
processen.
DEUTSCHE ZUSAMMENFASSUNG
Menschliche Zellen benötigen Energie, um wachsen und ihre Funktion aufrechterhalten zu
können. Das Molekül ATP ist ein energiereicher Zwischenspeicher, der in einer Vielzahl zel­
lulärer Reaktionen verwendet und hauptsächlich in Mitochondrien produziert wird. Diese
Zellorganellen sind zentrale Drehscheiben für den Stoffwechsel von zellulären Bausteinen.
Funktionieren sie nicht richtig, kann dies zu Erkrankungen führen. Ungefähr einer von 5,000
Menschen ist von einer mitochondrialen Erkrankung betroffen, die sich in einer vielzahl klin­
ischer Symptomemanifestieren kann. Wie diese Erkrankungen auf zellulärer Ebene entstehen
ist Gegenstand dieser Forschungsarbeit. Eine neue Generation sogenannter ”omics” Metho­
den erlaubt es, tausende Moleküle gleichzeitig zu vermessen. Ich verwende diese Methoden
zusammen mit Fliegen­, Maus­ und zellulären Modellen, um die systemischen Auswirkun­
gen schadhafter Mitochondrien zu verstehen. Diese Studien zeigen auf eine neue Art und
Weise, wie komplex die Regulierung von Stoffwechselvorgängen abläuft. Außerdem bieten
die translationalen Ansätze neue therapeutische Perspektiven für Patienten mit mitochondri­
alen Erkrankungen und bei Stoffwechselstörungen in Alterungsprozessen und Krebs.
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ABSTRACT
The human body consumes vast amounts of metabolites that are transformed into one another,
modified to useful building blocks and broken down to harvest their energy. Mitochondria are
at the core of this metabolic turnover and oxidative phosphorylation provides most cellular
ATP in almost all human tissues. Despite the variability of metabolite and oxygen supply,
mitochondria can readily adapt to their cellular niche. This requires a general flexibility in
the expression patterns of the roughly 1,150 mitochondrial proteins, and fine tuning of protein
actions. Failure to meet the cellular metabolic demand causes a wide range of tissue specific
symptoms in human.
This thesis explores the use of high­throughput omics techniques in understanding enzy­
matic remodeling during mitochondrial disease. In the first part, I introduce the reader to the
concepts of systems biology, and broadly discuss current methods and tools with a focus on
mitochondria. Then, I describe the fine­tuning of mitochondrial function by post­translational
modifications, in particular protein methylation and phosphorylation, and how this links to the
large metabolic network of the one­carbon cycle. I conclude with primers on mitochondria in
development and mitochondrial RNA metabolism. After that, I will present four publications
in light of the discussed concepts and methods:
In study I, we find that the highly abundant metabolite S­adenosylmethionine is indis­
pensable for mitochondrial function. Its cytoplasmic production controls mitochondrial func­
tion by regulating iron­sulfur clusters biosynthesis and stability of the electron transport chain
complex I, which has implications during ageing and cancer development. We apply a novel
labeling method and mass spectrometry­based proteomics to identify 205 high­confidence
methylation sites on mitochondrial proteins in fruit flies, and validate several by targeted pro­
teomics in mouse and human.
In study II, we describe SILAF, a novel and highly efficient method to label amino acids in
the fruit fly proteome. We exploit SILAF to characterize the mitochondrial phosphoproteome
in a fly model of mitochondrial disease, and we pinpoint two regulatory phosphorylation sites.
In study III, we investigate the role of the scaffold protein SQSTM1/p62 in neuronal de­
velopment. We find that the protein is required for differentiation of patient­derived neuronal
epithelial stem cells, caused by an impaired switch from glycolytic to oxidative metabolism.
In study IV, we use various fruit fly models to examine the interactions of proteins in mi­
tochondrial RNAmetabolism. Using transcriptomics, we identify leakage of double­stranded
RNA into the cytosol when mitochondrial RNA degradation is impaired and we suggest that
this contributes to increased susceptibility to infection upon mitochondrial dysfunction.
Our studies take a novel view on mitochondrial dysfunction, and our post­translational
modification screens give insight into a novel layer of complexity in the cell. The studies
expose the opportunities and challenges of data­driven life science and can serve as a primer
towards a digital representation of mitochondrial disease.
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The world is everything that is the case.
Ludwig Wittgenstein, Tractatus Logico­Philosophicus (1922)
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1 INTRODUCTION
1.1 What is systems biology?
A doctoral thesis with systems biology in its title is expected to be clear about this term.
Provokingly, it cannot be. After the human genome project had been completed in 2001,
the emergence of this linguistic compound coincided with a rapid progression of computing
power and human imagination for how to use computational resources. This has opened up
new possibilities for this young field, and hence has continuously modulated and shaped the
definition of the term until today [1].
A unifying aim of systems biology is to understand the larger picture of a living entity as
a sum of individual reactions in order to explain its behavior. Thereby, the focus can be a cell,
tissue, a whole organism or beyond. To get an understanding of such a system, it is necessary
to have knowledge about the individual components and their interactions. Rainer Breitling
suggested three aesthetic qualities of systems biology: diversity, simplicity and complexity
[2]. The term diversity appreciates the elements of a system and recognizes that these are
different from one another, for instance the proteins in a cell or the cell types in a tissue. As
Darwin proposed, diversity is a product of evolutionary selection, and thus the system itself
is blind. Researchers aim at finding patterns and causation in systems that follow a number
of simplistic working models in order to understand how the entity works. The most striking
difference of a systems compared to a molecular biology approach is that systems biology
strives towards assembling many simple models into complex networks in order to mimic the
behaviour of a living unit, rather than to reduce a complex system to simple building blocks.
Following this school of thought, systems biology emerges as a largely data­driven science
that marries biology with technological development and computational tools [3].
Cells require vast amounts of energy for homoeostasis and growth, and to fulfil special­
ized functions like secretion of enzymes or propagation of action potentials. The bioenergetic
demands of these processes limit the complexity of prokaryotes [4]. Following the current
dogma, the endosymbiotic integration of α­proteobacteria that formed the early mitochon­
dria was a key evolutionary event that allowed the transition from unicellular prokaryotes to
multicellular eukaryotes [5]. This thesis work studies the consequences of dysfunctional mi­
tochondria in a multicellular context. The aim is to adapt and apply tools to map the diversity
of mitochondria, to generate hypotheses on the etiology of mitochondrial dysfunction, and to
build novel functional networks that are useful in understanding human disease.
1
1.2 The power of eukaryotes – mitochondria
Mitochondria are organelles that form dynamic networks in eukaryotic cells. Under aerobic
conditions, they are able to generate large amounts of ATP, which serves as an energetic cur­
rency in cellular processes including enzymatic reactions, cytoskeletal remodeling and main­
tenance of membrane potentials. The α­proteobacterial ancestors of mitochondria [5] lost
and gained numerous genes and functions in exchange with the host cell during the course of
about 1.5 to 2 billion years [6]. Yet, almost all eukaryotic mitochondria retained some bac­
terial hallmarks, including a double membrane and an origin­of­replication bearing, coding
DNA molecule.
The size, shape and genetic content of mitochondrial DNA (mtDNA) varies substantially
across eukaryotic kingdoms [7]. The human mitochondrial matrix harbors circular, double­
stranded mtDNA molecules, which are 16.3 kb long and thus small in contrast to the nuclear
genome. Each organelle contains multiple copies of mtDNA. Depending on the cell type [8,
9], the copy number ranges from 3x103 per fibroblast [10] to 105 in one oocyte [11]. The
mitochondrial genome contains information for 13 proteins of the ATP­generating oxidative
phosphorylation (OXPHOS) system, and further for two ribosomal RNAs and 22 transfer
RNAs that form parts of an intra­mitochondrial protein biosynthesis machinery [12]. How­
ever, the genetic information for most of the mitochondrial proteins including the largest part
of the OXPHOS system is encoded in the nuclear genome. Most of the 1,136 recognized hu­
man mitochondrial proteins [13] are synthesized on cytoplasmic ribosomes and transported
as unfolded polypeptide chains across one or both organellar membranes by specialized ma­
chineries [14].
The mammalian OXPHOS system consists of five multiprotein complexes that convert a
reductive potential stored in electron carriers into ATP (Figure 1). The most prominent re­
duction/oxidation (redox) reactions upstream of OXPHOS occur as part of the tricarboxylic
acid (TCA) cycle, which integrates multiple catabolic and anabolic pathways, such as gly­
colysis, fatty acid degradation and amino acid turnover. The TCA cycle of a non­fasting,
non­ischaemic cell reduces both free oxidized nicotinamide adenine dinucleotide (NAD) to
NADH and covalently bound flavin adenine dinucleotide (FAD) to FADH2 [15]. These, in
turn, reduce iron­sulfur clusters in complex I and complex II, respectively. Driven by a pro­
gressive increase of cluster affinity, electrons flow through ubiquinone, complex III and cy­
tochrome c (cyt c) to complex IV, where the reaction with oxygen yields water. The electric
mobility of electrons is used by all OXPHOS complexes but complex II to establish a negative
chemiosmotic gradient across the inner mitochondrial membrane. This drives a proton flux
through complex V into the mitochondrial matrix that converts kinetic into chemical energy
as ATP. Electrons can enter the OXPHOS system not only via the TCA cycle, but multiple
further redox reactions in the cell are known that either generate NADH or reduce ubiquinone

























Figure 1: Schematic view of the OXPHOS system. By oxidation of NADH and TCA cycle substrates, elec­
trons enter the electron transport chain in the inner mitochondrial membrane. They are passed along redox
centers in complex I to IV, ubiquinone (Q) and cyt c onto oxygen. The conformational change of OXPHOS sub­
units pumps protons (H+) into the intermembrane space and establishes a concentration gradient and membrane
potential Ψ that is harvested at complex V to produce ATP.
1.3 Monogenic mitochondrial disorders
The stoichiometry of OXPHOS complexes is tightly regulated [16] and OXPHOS activity
meets the energetic demands of a certain cell type, developmental phase or circadian activity
profile. It is thus not surprising that the clinical picture of monogenic mitochondrial disorders,
which are caused by either mtDNA or nuclear DNA mutations, is extremely heterogeneous.
Any age group can be affected, but symptoms arise predominantly in the first three years of life
[17]. The combined prevalence of monogenic mitochondrial diseases is at least one case per
4,300 individuals reported for North East England [18], and rises profoundly in regions with
founder mutations and/or intertwined family trees [19]. Any organ can be affected, although
symptoms are primarily evident in energy­demanding tissues: brain and optical nerves, heart
and skeletal muscle, liver and lung [17]. In certain cases, symptoms can be grouped to syn­
dromes, for instance Leigh syndrome, which predominantly presents in young children with
brain lesions and a subsequent decline in cognitive functions [20]. Since the technical and
economic advancement of whole­exome and whole­genome sequencing in combination with
global efforts for patient report databases, a biochemical defect in OXPHOS function can be
linked to a disease­causing gene in more than 60% of all cases [17].
Yet, the diagnosis of mitochondrial diseases remains complex. Beyond monogenic disor­
ders, a growing body of evidence points towards a mitochondrial involvement also in multi­
factorial diseases like amyotrophic lateral sclerosis [21], Parkinson’s [22] or autoimmune dis­
eases [23]. The underlying molecular observations are not limited to dysfunctions of the
OXPHOS system, but include the various roles of mitochondria in calcium homeostasis,
metabolism, iron­sulfur cluster biosynthesis and apoptosis [24].
3
2 THE SYSTEMS BIOLOGIST’S TOOLBOX
2.1 omics technologies
Data­driven life science has been enabled by methodologies with the suffix omics, derived
from the word genome introduced in 1920 [25], that aim at comprehensively quantifying cel­
lular states in combination with computational data processing. The last two decades have
seen a profound decrease in costs, and several omics techniques such as whole­genome se­
quencing are used in clinical practice today [26]. Each method is able to capture one level
of biological complexity and multiple omes complement each other. A selection of these that
are relevant to this thesis work are discussed below.
2.1.1 Transcriptomics
The term transcriptomics broadly comprises all methods that aim at quantifying the sum of
RNA in a cell, including methods like expressed sequence tags [27] and microarrays. This
thesis work only covers massive parallel RNA sequencing (RNA­Seq), which in itself has
evolved into approximately 100 distinct methods that enable insight into various aspects of
cellular transcriptomes [28]. Most RNA­Seq applications aim at differential expression anal­
ysis, as it is used herein, alongside more specialized applications such as isoform­sensitive
[29], single­cell [30], spatial [31] and structural RNA­Seq [32].
Three major platforms have emerged to provide various kinds of biological insight: (1)
short­read, (2) long­read cDNA and (3) long­read direct RNA­Seq. While direct RNA­Seq is
performed on RNA without conversion, short­ and long­read sequencing rely on enzymatic
cDNA synthesis with a reverse transcriptase. Currently, short­read sequencing is the most
robust technique for high­throughput sequencing, and biases in both library preparation and
sequencing are well understood [28]. However, owing to its use of short fragment sizes with
less than 200 bases, the identification of transcript isoforms can be compromised. This is of
particular relevance for assembling reads from very long RNA species including polycistronic
mitochondrial transcripts in disease conditions with processing defects. In addition to whole
exome and whole genome sequencing [33], transcriptomics is emerging as a valuable tool
in diagnosing rare diseases. It is the most informative omics technology in cases of cryptic
or erroneous splice sites and allelic exclusion [34] when the bioinformatic pipeline allows
alignments against whole genome libraries instead of cDNA libraries.
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Figure 2: The omics trilogy. (A) A short account of methods used in this thesis work. Top to bottom: sample
type, technology and key concepts, technical schematic. (B) The author’s subjective view on key parameters of
the methods as they perform today. T: Transcriptomics; P: Proteomics; M: Metabolomics.
2.1.2 Proteomics
While the transcriptome contains the plans for the future functional building blocks of a cell,
the proteome reflects the current set of working protein units. Therefore, an accurate and
complete proteome quantification is more informative about the state of a cell than its tran­
scriptome. However, the challenge of quantifying proteins is inherently more complex com­
pared to RNA, currently limiting the amount of information that can be obtained from a single
proteomics experiment.
About 20,000 human genes give rise to potentially 230,000 different transcripts accord­
ing to the 2020 ENSEMBL release, including variants and non­coding genes [35]. Of those,
50,000 are protein coding mRNAs [36]. The UniProt database lists 76,000 protein entries at
the time of writing [37], but this number grows exponentially when post­translational modi­
fications (PTMs) are taken into account [38]. Although post­transcriptional modification of
RNA occurs, post­translational modification of proteins seems to be a much more widespread
regulatory mechanism. The unique molecular form of a protein is termed proteoform [39],
and one [40] to six million [38] proteoforms have been estimated per cell. Determining the
molecular identity and quantity of a proteoform requires either an affinity­based method, in
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which the specificity of the affine reagent must be known, or a destructive approach that dis­
assembles the molecule in a coordinated manner. Affinity­based methods like antibody­based
Western blotting or immunohistochemistry are extremely valuable research tools in molecular
biology, and large screening efforts like the Human Protein Atlas combine low­multiplexed
antibody­based protein detection with high­throughput microscopy [41]. However, these ap­
proaches are limited in their potential to find novel proteoforms.
The advent of proteomics using liquid chromatography, coupled to tandem mass spec­
trometry (LC­MS/MS) opened up possibilities to quantify thousands of proteins within a short
time. LC­MS/MS is a powerful tool to identify novel proteoforms [42]. Yet, the method is
constrained by the complexity of cellular samples. The dynamic range of the proteome, that
is the quantity range from the least to the most abundant protein, by far exceeds the dynamic
range of the transcriptome. While the transcriptome is estimated to range from 0.5 to 50,000
transcripts per cell, arising to five orders of magnitude [43, 44], the cellular proteome spans
approximately one copy to ten million protein copies, or an estimate of seven to eight orders
of magnitude [44, 45]. Furthermore, while the four building blocks of RNA and cDNA can
be reproduced one by one through Watson­Crick base pairing in millions of simultaneous
reactions, current methods to quantify proteins cannot be efficiently parallelized yet and the
signal of low­abundance proteins cannot be amplified. Therefore, although the most abundant
proteins can be quantified by LC­MS/MS within hours, capturing the low abundance range
is time consuming and laborious [45]. Despite the methodological constraints, the proteome
reflects the state of a cell more accurately than the transcriptome [44] (see also chapter 2.6),
and much research is being performed to solve the problem of dynamic ranges.
This thesis work uses discovery­ and validation­oriented mass spectrometry (MS)­based
proteomics techniques to pinpoint novel cellular proteoforms and to map PTMs. A variety of
approaches have been developed for ionization, mass selection and detection, and many are
in active development to match specialized applications like single­cell proteomics [46]. By
far most MS­based proteomics experiments follow a bottom­up work flow with LC­MS/MS
that requires digestion of proteins into peptides [47]. In brief, proteins are extracted from a
sample with chaotropic and reducing agents that destroy higher order protein structures. The
proteins are digested into peptides using an endoproteinase with a known cleavage pattern.
The most commonly used enzyme, trypsin, cuts C­terminally after lysine and arginine and
produces a set of peptides with an optimal length range for MS­based protein identification
[48]. However, depending on the application, a variety of endoproteinases can be used [49].
For instance, study I further relies on chymotrypsin that increases coverage of hydrophobic
amino acid stretches, which are prevalent in mitochondrial membrane proteins. After digest,
the produced complex peptide mixture is subjected to LC­MS/MS that combines separation
by hydrophobicity on a reversed­phase high pressure liquid chromatography columnwith ion­
ization, separation by mass­to­charge (m/z) of charged peptides, and selective fragmentation
of a subset of abundant peptides. The intensities per m/z beam of both the intact ionized pep­
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tide and its fragments, called spectra, are recorded. Peptide sequences can then be assigned
by matching measured spectra with in silico predicted fragmentation patterns using a library
of protein sequences.
As the mass of a post­translational modification is known, the predicted fragmentation
patterns can be extended by a possible number of PTMs per peptide. However, this increases
the search space dramatically, and potentially 98,000 proteoforms of human histone H4 exist
when just considering the 13 most common PTMs [40]. More complex searches impose a
computational problem and decrease the sensitivity and specificity of searches at a set false
discovery rate (FDR), in part due to similar or identical masses of de facto different peptides.
Therefore, there is a crucial need for both methodological and computational development,
and for accurate libraries of proteoforms in order to limit and speed up spectral searches to
biologically relevant hits.
2.1.3 Metabolomics
Metabolites are the downstream products of genes, transcripts and proteins, causing them to
be the most dynamic component in an intertwined cellular system [50]. Metabolic networks
provide the building blocks and energy for cell maintenance and growth, and shape cellular
behavior by modulating signaling pathways [51]. In 1965, the Nobel prize winner Ernst Boris
Chain listed ”the study of enzymatic reactions leading to the recognition of metabolic path­
ways” [52] as one of the ten landmarks in the history of biochemical research. Although Chain
did not state that this discovery process was completed, the metabolic maps that are taught in
biochemistry classes today mostly date back to the 1960s [53]. Only recently, technical ad­
vancements lead to the realisation that the metabolome is far more complex than anticipated.
This has caused new excitement to discover novel metabolites and metabolic pathways [53].
A number of methods are available to map and quantify metabolomes, although LC­MS
is the predominant technique for discovery metabolomics [53]. As above, the readout is the
m/z ratio of molecules after chemical separation, ionization and mass selection. The signals,
called features, are then mapped against a library of known metabolites. This is currently
the bottleneck of metabolomics, in part because the full content of metabolite libraries is not
known, which renders the metabolomics data scientist blindfolded towards the upper limit of
the reference database [54]. In addition, while 21 amino acids constitute the human proteome,
the structural building blocks of metabolites are combinations of atoms, with an exponentially
higher likelihood for identical or very similar masses of two compounds that are actually
structurally different. Thus, powerful LC techniques are pivotal to separate two chemically
distinct compounds. Indeed, approaches to match computationally predicted with real­world
retention times are transforming the field into a treasure box for biological discovery [55].
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2.2 Omics beyond steady state
The quantification of transcripts, proteins or metabolites is a snapshot of cellular components
with reasonable information when the studied model system is at steady state, for instance
immortalized cell lines that have been kept in culture without nutrient restriction. However,
once the cells are stimulated by, for instance, changing culture media or through genetic in­
sult, they will adapt to meet the new demands. Capturing these dynamics requires additional
dimensions in an experiment. This is of particular interest in search for the primary cause of
monogenic disease, in which the molecular role of a dysfunctional protein is yet unclear.
Experimentally, the extra dimension can be added either through consecutive sampling at
various time points or by introducing a pseudo­temporal axis through sampling at the same
time but from different biological specimens. A powerful tool for the first approach involves
stable isotope­labeled tracer molecules and MS to capture proteome and metabolome dynam­
ics. For the popular application stable isotope labeling of amino acids in cell culture (SILAC),
cells are grown in defined culture media in which all or selected ”light” amino acids are ex­
changed for biotechnologically synthesized and chromatographically enriched ”heavy” amino
acids [56]. In these, 1H hydrogen, 12C carbon and/or 14N nitrogen atoms are exchanged to
non­radioactive 2H deuterium, 13C and 15N isotopes, respectively. After media change, the
heavy labels are incorporated into proteins and amino acid­derived compounds. SILAC can
be used to quantify protein turnover during metabolic pulse labeling, as the proportion of la­
beled amino acids in a peptide backbone is dependent on de novo synthesis of its protein in
the presence of the label [44].
In principle any labeled compound can be used, with the limitation that the light coun­
terpart must be either completely replaceable in the culture medium or the baseline heavy­
to­light ratio must be known prior to the experiment. For instance, custom­prepared media
with metabolic 13C­labeled precursors were used to deeply label the metabolome of human
cancer cell lines and gave insight into the activity of metabolic pathways and the origins of
secondary metabolite components [57]. Thus, by measuring the heavy­to­light ratio at vari­
ous timepoints, the dynamic flow of metabolites, termed flux, in a defined metabolic network
can be reconstructed [58].
2.3 Model systems
2.3.1 Cell culture
Homogenous cell populations that are kept at precisely monitored conditions are highly useful
models to reduce the complexity of biological problems and to minimize data background
noise. Therefore, fewer replicates are required for robust statistics, which decreases analysis
time and costs. A wealth of methods has been optimized for cells in culture, including RNA
interference, over­expression systems and manipulations on genome level.
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Cell culture models can be distinguished by their provenance and possibility to main­
tain them over longer periods of time. Cell lines originate from tumor tissue or have been
immortalized by genetic inhibition of cell cycle blocks [59]. Thus, large quantities of genet­
ically identical cells can be grown within a short time, which allows multiplexing of genetic
or drug screens [60]. While cell lines are a widely used and valuable research tool, cellular
metabolism has adapted to sustain continuous growth under set culture conditions and data
has to be interpreted with great care. By contrast, primary cells are taken from an intact tissue
and maintain their potency state. Patient­derived primary cells like fibroblasts or myoblasts
are the only ethically acceptable route to test hypotheses that require experimental interven­
tion in a set (epi­)genetic background. Since the discovery that pluripotency can be induced
in mouse embryonic and adult fibroblasts by expression of four transcription factors [61], cell
models resembling a multitude of tissues can now be evoked in culture from starting material
of a different lineage such as fibroblasts. This is of great help in studying diseases that affect
the central nervous system [62, 63] including inborn mitochondrial and neurodegenerative
disorders [64]. For instance, patient fibroblasts can be reverted to pluripotent neuroepithelial
stem cells (NESC) that give rise to mature neurons when a specific differentiation program is
induced (see chapter 9.3).
Reprogrammed cells like NESC offer a unique window to study molecular mechanisms
of the human brain. However, the major drawback of cell culture models is the lack of tis­
sue complexity. As an example, the metabolism of neurons is tightly linked to surrounding
astrocytes that release lactate upon neuronal activity [65]. Therefore, a systems view of cells
in culture has to take the simplicity of the model and its inaccuracy in mimicking a tissue
setting into account. The highly artificial composition of cell culture media causes adapta­
tions of metabolic pathways so that disease states can be either hidden or exacerbated in omics
datasets, and is has been shown that components of culture media affect gene essentiality [66].
Furthermore, cells in almost all organs are confronted with much lower oxygen concentration
than atmospheric 21% in many tissue culture experiments, and pathways related to mitochon­
dria, iron­sulfur cluster and lipidmetabolism are particularly susceptible to inadequate oxygen
partial pressures [67]. One solution has been the development of three dimensional cell cul­
ture systems resembling human organs. While the reproducibility of these human organoids
still suffers from the variety of protocols and standards used in different labs [68], they have
the potential to accurately resemble the physiology of organs and complement or even replace
animal­based research.
2.3.2 Fruit flies
Since Thomas Hunt Morgan and colleagues established the fruit flyDrosophila melanogaster
(Dm) as a model system more than one hundred years ago, a wealth of tools have been de­
veloped for this working horse of biological research [69, 70]. Numerous hallmark findings
have been made especially in the field of developmental biology, which left traces inDm gene
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names: white, glass bottom boat or toll­like receptors are gene names, but describe the phe­
notype of flies deficient for that particular gene. In the field of mitochondrial disorders, the
fruit fly has proven to be a powerful in vivomodel to understand the function of novel disease
genes [71, 72] due to short generation times, comparably low maintenance costs and, most
importantly, the wealth of genetic tools. Commercially available fly lines allow the knock­
down or over­expression of most fly genes, which makes models for genes of interest rapidly
available in the laboratory [73].
In 2000, the fly was the second almost completely sequenced multicellular organism [74],
and its prospects were therefore promising to become a valuable tool in the era of high­
throughput biology. The genome has been fully annotated since 2003 [75] and a fly peptide
atlas has been established [76] that forms the basis for larger transcriptomic and proteomic
screens. Several developmental proteomes have been established by label­free quantifica­
tion, of which the latest comprises 15 developmental stages [77]. The most studied PTM
in flies is phosphorylation, which has been assessed in embryos [78] and as a differential
phosphoproteome in cold exposed flies compared to controls [79]. Differential proteomics
in flies, however, has been less applied, in part due to missing tools such as powerful label­
ing methods. SILAC is the gold­standard for experimental multi­step procedures involving
LC­MS/MS and allows accurate PTM quantification [80]. Thereby, organisms are grown on
medium that contains non­radioactive, heavy amino acid isotopes, mostly lysine and arginine.
SILAC for flies has been established by several research groups [81–83], and all approaches
were based on feeding labeled yeast. In practice, these methods are financially and techni­
cally difficult [84] and undesirable conversion of amino acids has been shown [83], which
depresses the signal of a labeled fraction and compromises the reliability of accurate peptide
quantification.
2.3.3 Mouse
Metabolism is highly tissue specific on transcript, protein and metabolite [41, 85, 86] level.
Cell culture models can only in part reflect this metabolic diversity and the various clini­
cal symptoms of inborn errors of metabolism. The fruit fly is a valuable compromise be­
tween tissue complexity and biological simplicity. However, individual tissues are difficult
and laborious to dissect, and tissue organization and function are often fundamentally dif­
ferent to humans. Although ethically more challenging (see chapter 8.7), the mouse allows
modeling of human disease in a much more intricate manner. A wealth of genetic tools and
well­established research infrastructure make the mouse an obvious choice for many ques­
tions regarding tissue­specificity of metabolic dysfunction. Several valuable mouse models
of mitochondrial disease have been developed. As an example, knock­out of the mitochon­
drial transcription factor A (TFAM) causes severe depletion of mtDNA in mice [87]. Tissue
specific deletions of TFAM have been used to study the consequences of mitochondrial dys­
function in various organs, including muscle [88], heart [89] and T­cells [90].
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When a full­body knock­out of a gene is lethal at embryonic stage, the access to samples
is limited and alternative experimental approaches are favorable. Cre­expressing lines are
frequently used to knock­out loxP­site flanked genetic segments in a specific tissue, which
depends on the chosen Cre­promoter, and these models are often viable. Additionally, mouse
embryonic fibroblast (MEF) cells can be obtained from embryos by dissection. After immor­
talization, MEF cells can be kept in tissue culture with the advantages and disadvantages of
cell culture discussed above. Yet, MEF cells can be seen as a valuable and ethically more
acceptable model during the discovery phase of a project.
2.4 The dream of the digital cell
For systems biology to be useful in our quest to understand life, its goal must be to represent
cells in a digital way so we can make predictions about cellular actions under set circum­
stances. In a clinical setting, for example, a useful binary model of a cell can pinpoint the
genetic mutation that causes mitochondrial dysfunction from whole genome data and it can
accurately predict the aberrant metabolic fluxes. This also applies for proteins whose func­
tions are not yet known, and this thesis work has contributed to elucidating the molecular role
of several proteins by constructing rudimentary digital representations of cells.
Biological systems are often described as complex, but as Hiroaki Kitano pointed out, the
non­linear interactions of multifunctional components lead to a rather coherent behavior [91].
Networks are useful humanized descriptions of these interactions, which are characterized
by nodes (components: genes, transcripts, proteins, metabolites, etc.) and edges (modula­
tory interactions between components: transcription factor binding, RNA interference, post­
translational modification, protein­protein interactions, etc.; Figure 3). After several hundred
years of developing a strict scientific ethos based on pattern recognition and linear causative
relationships, especially within molecular biology, we now face the challenge that the con­
structed networks from single and multiple omics datasets become incomprehensible for the
human mind. In other words, the networks are perceived as complex.
Systems biology has the power to give unprecedented and transformative insight into liv­
ing systems, and a number of tools help us to overcome the limitations of data integration and
interpretation [92]. Known protein­protein interactions can help in identifying the primary
interaction partners of a protein of unknown function. The popular web­based tool STRING
[93] collects and scores publicly available interaction datasets and uses these to find edges be­
tween hits of an omics screen. For instance, supposedly a gene encoding protein X is knocked
out and a proteomics screen identifies that protein Y is lost, then one conclusion can be that
X interacts with and stabilizes Y (see study II, in which SLIRP is lost upon knock down of
DmLRPPRC1). While highly useful for low­throughput studies of defined model systems,
protein­protein interaction networks are more likely to fail when the precise insults to an in­
teraction network are either not known as in the case of unknown disease­causing variants
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or multi factorial with environmental contribution. Moreover, incomplete data and varying
annotation levels limit this approach further [93].
The interactions on genome level can be computed from gene essentiality screens, which
are almost exclusively performed in cell lines. A gene is essential if its gene product is re­
quired for cellular survival, and vice versawhen its loss compromises cellular fitness [94]. The
human Cancer Dependency Map combines genetic screens, drug sensitivity, and other omics
datasets from various cell types to predict the vulnerability of cells to the loss of gene products
[95]. For instance, the Achilles dataset comprises cell viability scores after CRISPR/Cas9­
based screening of 18,000 genes in 800 human cancer cell lines [96]. Correlating the via­
bilities of various genes with each other, or with further omics datasets can give insight into
relationships between gene products. For instance, Jain et al. used gene essentiality data from
the Achilles project and correlated it with metabolite levels in the corresponding cell lines,










Figure 3: A simple network model. The
network is centred on the node α that has four
edges to direct direct partners βi, of which
some interact with each other and further γ
partners and so forth.
Grouping proteins with known function into func­
tional categories is called pathway analysis and is
another popular approach to interpret large datasets.
This is appealing because it reduces the complexity
of a dataset and has high explanatory potential [97].
Over­Representation Analysis (ORA) comprises the
first generation of pathway analysis tools [98]. A list
of interesting elements is chosen on the basis of, for
instance, p values after differential expression analy­
sis, and the list is then statistically evaluated against
all detected elements. Each element is annotated with
the pathways it contributes to using libraries such as
Gene Ontology (GO) resources [99] or the Kyoto En­
cyclopaedia of Genes and Genomes (KEGG) [100],
and over­represented pathways in the interesting list are returned. The main problem is the
arbitrary user­based choice of a cutoff value to define the list of interesting elements. The next
generation of functional class scoring pathway analyses [97], for instance Gene Set Enrich­
ment Analysis (GSEA), follows a similar functional annotation strategy. GSEA uses ranked
lists that are most often based on changes in expression and that contain every detected ele­
ment instead of just a selection [101] as in ORA. While this approach is more robust towards
outliers, it is bias­sensitive when there is no real biological difference. Furthermore, ORA and
GSEA suffer from incomplete pathway annotations or assignment of one element to several
pathways, which aggravates the biological interpretation. Efforts are being made to standard­
ize library terms [99], and a third generation of pathway topology­based models is on its way
that combines pathway analysis with known interactions [97].
With a growing number of datasets, biologists must pair up with computer scientists to
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solve the more and more complex omics puzzles. The digital cell is still a dream, but user­
friendlymachine learning algorithms delivered for instance via the TensorFlow interface [102]
will contribute greatly in unsupervised network construction to gain biological insight [103].
Importantly, this does not alleviate the need for high­quality molecular follow­up studies by
experimental molecular biology .
2.5 Open source data access
Science has become a data intensive enterprise, and it will continue to move into this direc­
tion with decreasing costs, more standardized protocols and better accessibility to omics core
facilities. Moreover, instead of producing new datasets cross­disciplinary studies can greatly
profit from re­using and re­purposing already existing data [104]. However, this approach
continues to be hampered due to lack of clear best practices in data documentation [105].
The FAIR principles (Findable, Accessible, Interoperable, Reusable) that were formally
published in 2016 aim at framing guidelines for the necessary infrastructure and policies [106],
and an increasing number of grant agencies and scientific journals require public data depo­
sition [107]. Several platforms including the Gene Expression Omnibus (GEO) of the U.S.
National Center for Biotechnology Information (NCBI) and the PRoteomics IDEntifications
(PRIDE) Archive hosted by the European Bioinformatics Institute have emerged to support
large­scale data deposition and annotation, and to promote the re­usage of datasets. PRIDE
Archive stored almost 13,000 datasets at the time of writing predominately from human ma­
terial [108], and 293 were re­analyzed until September 2018 [109]. Yet, the observation that
this thesis provided 3.5% of all fruit fly datasets (5 out of 144 at the time of writing [109])
raises the suspicion that a large body of data is still not made public. With better mining tools,
the scientific community will profit from re­analyzing data and it will be exciting to observe
how the attitude towards data transparency develops in the near future.
2.6 Nuances of mitochondrial systems biology
Omics data analysis that is focussed on mitochondrial function faces a number of challenges.
Firstly, mitochondrial components do not necessarily give insight into a mitochondrial defect
when studied in relation to the rest of the cell. Fission and fusion events make the mitochon­
drial compartment highly dynamic, and the total mitochondrial mass can vary between cells
of the same cell type. Thus, a total omics dataset might help in observing a generalized loss or
accumulation of mitochondrial proteins, but this can reflect an upstream coordination through
master regulators such as PGC1α [110] rather than an intrinsic mitochondrial response.
Secondly, the majority of the nuclear transcriptome that encodes mitochondrial proteins
does not correlate with protein levels [111]. Consequently, this limits the usability of tran­
scriptomics data in mitochondrial systems biology (Figure 4). The reasons for this are un­
clear. The major part of the approximately 1,150 annotated human mitochondrial proteins
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Figure 4: Functional relevance of mitochondrial transcriptomic and proteomic data. Log2­transformed
expression ratios of TFAM knock­out mice against controls, quantified by transcriptomics and proteomics. Data
was grouped into functional pathways as indicated. Adapted with permission from Kühl et al. [111] under the
terms of the Creative Commons Attribution Licence 4.0.
[13] are nuclear encoded, synthesized on cytoplasmic ribosomes and imported into mitochon­
dria via a specialized one­way import machinery. There, a considerable fraction assembles
into large protein complexes like the mitochondrial ribosome or the OXPHOS system [16].
Thus, the lack of correlation could be a consequence of stabilizing proteins in complexes that
prevents their degradation, the absence of a direct translational feedback loop, or the above
discussed discrepancy of mitochondrial versus total cell protein mass.
Thirdly, whole cell metabolomics does not retain the subcellular spatial information. There­
fore, the organelles are typically enriched by differential centrifugation to quantify mitochon­
drial matrix metabolite concentrations. This process takes time and metabolites can diffuse
through solute carriers along a sharp gradient into the enrichment buffer. One solution has
been provided by the rapid antibody­based extraction of mitochondria [112]. However, this
requires the expression of a handle protein on outer mitochondrial membrane and the method
is currently only available for cultured cells.
Few tools and databases specialise on mitochondria. MitoXplorer uses manually curated
lists of mitochondrial proteins including functional annotations. It provides a web­based anal­
ysis tool that imports known protein­protein interactions and that subsets user­defined input
data into functional categories [113] for manual inspection. MitoCarta was first published
in 2008 [114] and has since then been a reference proteome for mitochondrial proteins. The
current version 3 [13] assigns hierarchical functional groups and suborganellar localization
to mitochondrial proteins. The precise localization of mitochondrial proteins has also been
mapped in Saccharomyces cerevisiae [115]. Moreover, the construction of mitochondrial in­
teractive protein networks has been facilitated by recent protein proximity mappings on a
global level [116] and with a focus on mitochondrial protein biosynthesis [117].
The comparably small set of proteins and the semi­autonomous characteristics make mi­
tochondria an exciting research object for systems biology. Many challenges on both the
experimental and computational level remain, but the integration of more large­scale datasets





PTMs are an energy­efficient mechanism to regulate the activity of proteins and diversify
the functions of proteomes [118]. With the advent of MS­based proteomics, a large number
of proteins was found post­translationally modified. To date, the PhosphoSitePlus inventory
version 6.5.9.3 [119] counts 486,000 individual PTMs throughout the cell including mito­
chondria, and there is increasing evidence for regulatory roles of mitochondrial PTMs [120].
Various types of chemical modifications have been described in mitochondria including phos­
phorylation, methylation, lipoylation, acetylation, ubiquitination, acylation (succinylation,
glutarylation, malonylation), succination, O­GlcNAcylation, and others (Figure 5). Some
of these are well established while others have been a matter of vivid debate such as acety­
lation [121] or will still have to face the discussion of their biological significance. In the
context of this thesis, only phosphorylation and methylation will be discussed, but several
key questions are of general importance in the field and described below.
Is a detected modification real or a technical artefact? Concerns have been raised that
sample handling can artificially introduce modification on certain residues. For instance, a
larger number of peptides were found methylated specifically after sodium dodecyl sulfate
(SDS) gel electrophoresis [122]. Similarly, it has been shown that tryptophan oxidation to
kynurenine and N­formyl kyrunenine is a gel electrophoresis­derived artifact [123]. More­
over, phosphorylation is isobaric with sulfation, which is an artifact after silver staining of
gels [124]. Gel­free sample preparation for MS counteracts these problems, although Nielsen
et al. showed that iodoacetamide treatment, which is often used during peptide production,
causes artifacts that mimic diglycine signatures of ubiquitination [125]. Thus, the assignment
of PTMs to mass spectra needs to be done with caution, and additional evidence using labeling
strategies or targeted MS is pivotal for high­confidence mapping of PTMs.
Is a target modified to a biologically relevant extent? Increased sensitivity of mass spec­
trometers allows the detection of low­abundance proteins and PTMs. An important parameter
to assess their biological relevance is the site stoichiometry or occupancy, which is the pro­
portion of a specific site on a given protein that is modified over unmodified [118]. The
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Figure 5: A selection of protein post­translational modifications. Note that several of the modifications can
occur on other residues as well. Here, only the most common modified amino acids are listed.
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ditions. For instance, a five­fold increase from 1% to 5% would correspond to an increase
from 20% to 100% [126]. However, the methodology for absolute quantification of site occu­
pancies has a number of limitations [118] and mere relative ratios between two conditions are
easier to obtain. The biological significance of low­abundance occupancy sites is not clear
yet [121] and the evaluation currently depends on prior knowledge or biochemical follow­up
studies.
Is the modification mediated by enzymes? Nucleophilic or redox­sensitive side chains of
amino acids can react with suitable metabolites such as acetyl­CoA without enzymatic catal­
ysis [127]. However, spontaneous reactions do not need to be random, and the specificity of
non­enzymatic reactions is an active area of research [127]. On the contrary, phosphoryla­
tion, methylation and ubiquitination require kinases, methyltransferases and ubiquitin ligases,
respectively, albeit non­enzymatic phosphorylation by inositol pyrophosphates has been re­
ported [128]. From an experimental point, the function of enzymatic PTMs can be studied by
both manipulating the target amino acid and by genetic perturbation of the modifying enzyme.
The latter approach avoids the problem that exchanging an amino acid to a non­modifiable or
constitutively modified analogue only approximates the chemical environment of the actual
modification, which is not a definite proof of the biological role of a PTM. For instance, glu­
tamic or aspartic acid are considered mimetics of phosphorylated serine due to their negative
charge and small size, while alanine resembles the non­modifiable amino acid [129].
Is the modification reversible? A number of non­enzymatic PTMs are irreversible and
signal cellular stress. For instance, succination of cysteine residues is a downstream conse­
quence of fumarate accumulation in the TCA cycle, and it has been shown that mutations
in fumarate hydratase lead to elevated succination of proteins required for iron­sulfur­cluster
synthesis [130]. Acetylation on lysine, on the contrary, can be removed by NAD+­dependent
SIRT3 in mitochondria [131]. This gave rise to the idea of a direct metabolic feedback loop
that omits the need of specific protein relays [121]. Few enzymatic PTMs can be removed
through designated proteins, such as phosphatases [132] and deubiquitinases. Demethylases,
however, appear to exclusively target histone tails [133], and non­nuclear demethylases have
not been identified to date.
Is the targetmodified insidemitochondria? Fewmodifying enzymes are targeted to mito­
chondria such as the methyltransferase NDUFAF7 [134] or the lipoyltransferase LIPT1 [135].
However, most modifications in mitochondria do not have a known corresponding enzyme,
which raises the hypothesis that polypeptide chains can be modified prior to mitochondrial
import. Indeed, it has been shown that the cytoplasmic enzyme PRMT1 is responsible formul­
tiple asymmetric dimethylated arginine residues on mitochondrial proteins [136]. The extent
of pre­import modifications and the underlying molecular mechanisms are still unknown.
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Are we done? Several reports suggest that at least 50% of all cellular proteins are phospho­
rylated at some point [137–139] in mouse, HeLa cell lines and yeast, with similar rates for
acetylation [140] and ubiquitination [141]. The rate of false positives as well as false negatives
is currently unclear, and Olsen andMann stated in 2013 that we will not have completed an in­
ventory of PTMs in the near future [42]. The limitations are in part related to the sensitivity of
mass spectrometers. In fact, new technical developments have led to ever­increasing sizes of
the modified proteome [121]. Additionally, most studies rely on classical peptide preparation
approaches using trypsin as an endoproteinase, which renders strongly hydrophobic peptides
as in membrane­bound proteins, and short and long tryptic peptides underrepresented [42].




Protein phosphorylation was the first post­translational modification to be mapped on glyco­
gen phosphorylase in 1956 by Edwin Krebs and Edmund Fischer [142]. Potentially due to
its scientific age and historical role in educating biochemistry students, phosphorylation is
well studied and to our knowledge the most abundant PTM. The modification is a covalent
addition of a phosphate group to hydroxy groups of side chains of serine (86% of all phos­
phorylated amino acids), threonine (12%) and tyrosine (2%) [143]. Although protein­protein
binding is not energetically more favorable upon phosphorylation [144], the modification
increases the interactive capacity of a protein because the dianionic phosphoryl group can
participate in hydrogen bonds and salt bridges with other residues such as arginine and lysine
[145]. Indeed, modified residues are preferentially located at the binding site of homo­ and
heterooligomeric complexes [146], and within disordered N­ or C­terminal regions [144]. For
instance, the aforementioned glycogen phosphorylase is phosphorylated at serine 14, which
causes a disorder­to­ordered transition of the N­terminal protein tail, subsequent homote­
tramerization, the exposition of the active site of the protein, and ultimately the activation
of the enzyme to degrade glycogen [147].
3.2.2 Screening and quantification strategies
Phosphorylation is operational in essential cellular signaling pathways, and aberrant stoi­
chiometry or mutations at the phosphorylated site contribute to a wide array of diseases such
as cancer [148] and Parkinson’s disease [149]. Reassuringly, inhibiting appropriate kinases
is a successfully applied therapeutic strategy [150]. The achievable depth of the substoichio­
metric phosphoproteome is limited by a number of factors that need to be considered during
experimental setup. Firstly, although a large fraction of the proteome can be phosphorylated
throughout time, only about 1­2% of the entire proteome are believed to bemodified at a given
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moment [151]. Therefore, if a complex protein sample is subjected to LC­MS/MS, most duty
cycles of the mass spectrometer will quantify unmodified peptides and low­intensity modi­
fied peptides might not be detected. Secondly, we and others have observed severely reduced
signals from phosphorylated over non­phosphorylated synthetic standards due to different
ionization properties, although this notion of phosphoproteomics has been challenged [152].
This suggests that phosphorylated peptides are less likely to be detected than their modified
counterpeptides.
Enrichment strategies have been developed to enhance the coverage of phosphorylation
sites in complex biological samples. Affinity­based enrichments with immobilized metal
affinity chromatography (IMAC) or metal oxide affinity chromatography (MOAC) are now
widely used, and several pre­enrichment fractionation techniques were optimized includ­
ing strong­cation exchange (SCX) and high pH reversed phase liquid chromatography (HpH
RPLC) [153]. However, since the publication of EasyPhos [154], which is a one­step pro­
tocol for enrichment of phosphopeptides with titanium dioxide (TiO2) as a MOAC material
without prior fractionation, TiO2­based enrichment has become the most widely used method
to obtain complementary phosphoproteomes.
A fundamental problem of enrichment strategies in general is the loss of information of
site stoichiometry, and the abundance of the corresponding protein has to be quantified in
a separate experiment [118]. In a label­free approach, the absolute occupancy of a site can
be compared between two biological conditions under the assumption that the abundance of
the unmodified peptide changes reciprocally to the modified counterpeptide [155]. However,
the requirement for accurate quantification is that the protein levels are unchanged in both
conditions, which is in practice not always achievable in a biological context. Furthermore,
the site occupancy must range between 10% and 90% so that the less intense peptides can
still be reliably quantified [118, 155]. Quantification of site occupancies from SILAC labeled
peptides is more robust and takes protein level changes into account [138]. However, it is
only reliable when the modification stoichiometry is in fact different between two samples
[118]. For this, a user­friendly add­on has been implemented in the classical proteomics data
analysis software MaxQuant [156].
3.2.3 Mitochondrial protein phosphorylation
Seminal work onmitochondrial protein phosphorylation has been performed in Saccharomyces
cerevisiae. Ameta­analysis by Frankovsky et al. listed 972 (67.6%) phosphorylatedmitochondria­
associated proteins and a total of 9,402 phosphorylated sites [132]. This converts to an average
of 6.76 sites per protein, which is either slightly more (6.05 in [132]) or considerably less (9.84
in the Fungi Phosphorylation Database [157]) than the total cell site­to­protein ratio. Most
sites do not have an annotated function. Growing yeast on either glucose or lactat/galactose
medium identified 670 sites in mitochondria and 90 were found differentially phosphorylated
[158], suggesting these sites associated with OXPHOS activity. Recently, it has been shown
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that mitophagic removal of mitochondrial proteins is selective and depends on the phosphory­
lation status of the target protein [159]. However, the specificity of this mechanism is unclear.
Prominently, the mitochondrial pyruvate dehydrogenase complex (PDH) is regulated by
phosphorylation through the activity of four PDH kinases that inactivate the complex, and
two PDH phosphatases that restore enzyme activity [160]. Several kinases and phosphatases
with multiple cellular localizations have been found in mitochondria, including the receptor
tyrosine kinases epidermal growth factor receptor (EGFR) and ErbB2 (reviewed in [161]).
An interesting body of work has been accumulated on the serine/threonine kinase cAMP­
dependent protein kinase (PKA). PKA associates with the outer mitochondrial membrane by
binding to A­kinase anchoring proteins (AKAP), which can sequester multiple proteins and
thus serve as signaling hubs [162]. For instance, by binding to AKAP121, PKA phospho­
rylates the pro­apoptotic protein BAD and counteracts apoptosis [163]. Moreover, PKA has
been localized to the inner mitochondrial membrane and matrix in several reports using im­
munoelectron microscopy and subcellular fractionation [164, 165]. Silencing of AKAP121
decreases intra­mitochondrial PKA levels [166], however, the mechanism of mitochondrial
import remains unknown as the protein does not contain a mitochondrial targeting sequence
[162]. Evidence for mitochondrial PKA function stems from PKA­dependent phosphoryla­
tion of the complex I subunit NDUFS2 [166] and ATPase Inhibitory Factor 1 (IF1) [167].
Although an intra­mitochondrial cAMP source for PKA has been proposed, it remains un­
clear whether the vast number of phosphorylations happen inside the mitochondrial mem­
brane boundaries, are added upon import as has been suggested [132], or are non­enzymatic.
Due to this conundrum, large­scale PTM screening efforts profit from rigorous biochemical
follow­up in order to prove that a particular site is real and of biological importance.
In Dm, phosphorylation within the mitochondrial compartment has not been widely stud­
ied. A total fly phosphoproteome study found about 500 phosphoproteins and 1,600 phos­
phopeptides, and changes of PTMs status upon cold exposure associated in particular with
microtubular networks [79]. In mammals, mitochondrial proteins related to OXPHOS and
metabolism were found differentially phosphorylated in obese mice [168, 169]. In contrast to
yeast, the modification was underrepresented in mice [169] and human cell lines [170]. Yet,
it is unclear if an intra­mitochondrial feedback loop via protein phosphorylation exists and
how monogenic mitochondrial disease shapes the modification landscape.
3.3 Methylation
3.3.1 Biochemical snapshot
The protein modification methylation is the addition of one or more CH3 groups to the amine
group of an amino acid side chain, predominantly arginine and lysine. However, non­canonical
methylation of histidine, glutamate, glutamine, aspartate, asparagine, cysteine, and protein






























Figure 6: Methylation is a multifaceted and small modification. (A) The formal charge, structure and size
of lysine trimethylation (marked with a rectangle) in comparison with other lysine modifications. From left to
right: the unmodified lysine residue, trimethylation, acetylation, propionylation, malonylation, butyrylation,
succinylation, glutarylation, biotinylation and myristoylation. Reprinted with permission from Minkui Luo
[173]. Copyright 2018, American Chemical Society. (B) Types of arginine and (C) lysine methyl­modifications.
adenosylmethionine (SAM), which is an abundant metabolite second only to ATP [172].
Compared to other PTMs, methylation is a small chemical group that retains the charge of
the modified lysine and arginine (Figure 6A) [174]. It enlarges the hydrophobic shell around
the terminal atoms of the side chain, and thus reduces the amphiphilic character of the unmod­
ified amino acid [173]. On lysine, the ε­N atom can become mono­, di­ and trimethylated,
which increases the mass of the residue by 14 Da, 28 Da, or 42 Da, respectively. Argi­
nine can be found mono­ and dimethylated, and dimethylation can occur both symmetric and
asymmetric (Figure 6B, 6C). Every consecutive methyl group reduces the hydrogen bond­
ing capacity of the amine group by one. Arginine is a particularly interactive residue that
often protrudes from protein surfaces, and its five hydrogen bonding donors enable protein­
protein or protein­nucleotide interactions [175]. The naked arginine can interact with two
moieties simultaneously through two amine groups, which allows the symmetric and asym­
metric dimethyl configurations. Albeit the positive charge is independent of the methylation
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state, methylation induces changes in charge distribution as shown by nuclear magnetic reso­
nance (NMR) spectroscopy [174]. However, the precise role of individual modification states
is not known and will require additional structural studies.
3.3.2 Screening strategies
Protein methylation is a subtle chemical event that elevates the hydrophobicity and spatial
requirements of an amino acid side chain. Yet, as a methyl group adds just 14 Da to a protein,
the methylated and unmethylated states are not distinguishable by size selection on Western
blotting. Discovery of novel methylation marks with traditional wet­lab techniques is thus a
time­consuming process. LC­MS/MS is a powerful technique to detect hundreds to thousands
of PTMs at once. In principle, it is required to screen for a 14 Da mass shift from an expected
peptide mass to detect a methyl­PTMs. This approach is, however, limited by several obsta­
cles [42]. Firstly, a mass spectrometer can only fully sequence a small number of peptides
per time unit, which decreases the likelihood that a medium or low­abundance methylated
peptide will be analyzed. Secondly, the methylation occupancy, which is the percentage of
a certain residue being modified, is usually low in the case of regulatory PTMs. Thirdly, to
confidently localize a methyl group on a certain amino acid, the fragmentation pattern of that
peptide has to contain sufficient information, which is not always the case.
Similarly to phosphorylation discussed above, strategies were developed for the enrich­
ment of methylated proteins or peptides over a non­methylated background. Immunoaffinity
enrichment involves antibodies that are coupled to agarose or magnetic beads. A set of an­
tibodies has been developed against mono­, symmetrical and asymmetrical dimethylation on
arginine and a pan­methyl antibody for lysine [176]. Together with a variety of fractionation
methods [177], the mono­methyl arginine antibodies led to the discovery of a large number of
methylation sites [178–180]. The false positive rate among those is unknown and likely high
[181]. Applying these strategies to lysine methylation has been difficult and tagged peptide
domains have been developed that bind mono­ and dimethyl lysine without sequence speci­
ficity [182]. However, these domains recognize only undigested proteins and not peptides,
and a profound background of non­methylated peptides negatively affects discovery depth.
In order to decrease the number of false positive hits and to provide a further in silico
search strategy, heavy methyl­SILAC was developed. By feeding cells with labeled methion­
ine [183], a 4 Da ”heavy” label is added to every SAM­derived methyl group. The finding of
a methyl group depends thus not only on a 14 Da shift of a light methyl group to an unmod­
ified peptide, but also an additional 4 Da heavy to light and 18 Da modified to unmodified
shift due to the heavy label. The dedicated software MethylQuant has been developed to
screen for mass shifts in complex methyl­SILAC data, which allows a consistent calculation
of FDR for methylated peptides across studies [184]. Interestingly, the labeled [13C2H3]­SAM
is slightly more reactive than its light counterpart [185], which can indicate a minor bias in
methyl­SILAC experiments.
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In addition to isotopic SAM, unmodified lysine residues can be blocked with formalde­
hyde or propionic anhydride that introduce distinct masses and furthermore efficiently block
trypsin digest at the modified residue. The specific cleavage pattern can thus be used to
distinguish the modification state at a certain lysine residue [173]. Furthermore, alkyne­
containing SAM analogues can be applied to introduce clickable modifications instead of
methyl groups [186]. The modified proteins are then clicked to biotin and enriched with
streptavidin­coated beads before digestion and LC­MS/MS [187]. Notably in the mitochon­
drial field, this approach has been successfully used to detect methyl­histidine on the complex
I subunit NDUFB3 [188]. The SAM analogues are powerful in detecting truly methylated
proteins in cell culture, yet at the expense of a high false negative rate. It is currently unclear
which structures of SAM­binding pockets allow the binding of analogues, and which poten­
tial targets will be omitted from labelling in a cell­wide screen [189]. Furthermore, the alkyne
instead of a methyl group will alter the local chemistry at the modified residue, and sites that
are of structural importance might not be covered well. However, promising solutions are




4.1 Flux of one­carbon units
A unifying early metabolic signature of a mitochondrial insult is an increase of mitochondrial
1C enzymes [24, 111, 190]. 1C metabolism comprises a set of reactions in both cytoplasm
and mitochondria to transfer 1C units and modify their oxidation state [191]. The cofactors
that carry 1C units within the main pathway are folates, a subsuming term for derivatives of
folic acid. Folates cannot be synthesized de novo in human cells and must be taken in with
a diet. Although natural diets contain almost exclusively 5­methyl­tetrahydrofolate (THF)
[192], the precursor folic acid is used as the artificial dietary supplement, which has to be
reduced in several NADPH­dependent reactions to be biologically active. These reactions
have been shown to be of minor physiological importance in humans and excessive intake of
the vitamin retains a large pool of unmetabolized folic acid in the blood that can cause adverse
effects [193]. However, folic acid profoundly decreases neural­tube defects in newborns [194]
and is indicated as a peri­conceptional dietary supplement [193].
Folates can carry one 1C unit at a time in different oxidation states, most importantly 10­
formyl­tetrahydrofolate (THF), 5,10­methylene­THF and 5­methyl­THF (Figure 7). Each
compound allows a different chemistry and is co­substrate to specific 1C­transfer reactions.
Cytoplasmic synthesis of purines is the largest sink of 1C units carried on 10­formyl­THF
in proliferating cells [191]. The required enzymes are localized in purinosomes in proxim­
ity to mitochondria. These structures have been shown to respond to mitochondrial stress,
suggesting a direct link between purine synthesis and mitochondrial function [195]. A minor
proportion of 10­formyl­THF [196] is further needed inmitochondria to formylate themethio­
nine tRNA recognition loop [197]. 5,10­methylene­THF is a co­substrate for serine synthesis
in both cytosol and mitochondria, whereby the methyl group is transferred onto glycine. Fur­
thermore, 5,10­methylene­THF is required for cytosolic thymidylate biosynthesis. This links
back to mtDNA­associated diseases as imbalanced nucleotide pools lead to mtDNA instabil­
ity [198]. 5,10­methylene­THF can be further reduced to 5­methyl­THF, which provides the
methyl group in the re­methylation of homocysteine to methionine, thus fueling the methio­
nine cycle (see section 4.2).
The cytosolic and mitochondrial route of 1C metabolism are linked via THF and formate;
other folates that carry 1C units cannot pass the mitochondrial membrane and have to be syn­











































































































































































































































































































































































































































































































































































































































































































sources are known including betaine, sarcosine and tryptophan [201]. The two compartmen­
talized pathways thus form a cycle, known as the folate­mediated 1C cycle. All reactions in
this cycle are reversible and their direction depends on the metabolic state of the cell. While
serine might be used up in one compartment, it is synthesized in the other one [191]. It has
been shown in cancer cells that the mitochondrial route is the predominant one [202] and the
transcript for the mitochondrial 1C cycle enzymeMTHFD2was the most up­regulated among
a broad tumor tissue panel [203]. A physiological driving force for a predominant mitochon­
drial route from THF to formate is potentially the high NAD+/NADH ratio in mitochondria,
thus favoring the oxidation of folates and generation of mitochondrial NADH. It has been
proposed that this contributes to redox homeostasis [202]. In agreement with this, the cytoso­
lic route is mostly consuming NADPH and sustains the backflow of THF into mitochondria
[204].
4.2 Control of S­adenosylmethionine synthesis
5­methyl­THF is required for the re­methylation of homocysteine to methionine by methion­
ine synthase, one of the two known vitamin B12­dependent enzymes. A salvage pathway ex­
ists in liver and kidney, whereby betaine­homocysteine methyltransferase (BHMT) abstracts
a methyl group from betaine to re­generate methionine [205]. Clearance of homocysteine
is essential for human health, and increased levels of plasma homocysteine correlate with
cardiovascular diseases [206] and stroke [207]. It has further been found that homocysteine
activates NMDA receptors on neurons and immune cells, which stimulate generation of reac­
tive oxygen species (ROS) and cell death [208]. Additionally, the enzyme adenosylhomocys­
teinase (AHCY) adversely favors the condensation of homocysteine with adenosine to yield
S­adenosylhomocysteine (SAH), which is a strong inhibitor of SAM­dependent methylation
reactions. In support for the arising pathological condition, increased homocysteine levels
were linked to a hypo­methylated cellular state [205].
The re­methylation of homocysteine to methionine initiates the methionine cycle, which is
formed by four reactions as shown in Figure 7 [209]. Methionine synthase (reaction 1) links
the 1C cycle with the methionine cycle, although the rate­limiting step of the methionine cycle
is the subsequent adenylation of methionine (reaction 2). The mammalian genome contains
three methionine adenosyltransferase (MAT) genes that can catalyse this reaction, which as­
semble to three known homo­ and dimeric isoforms. MAT I, a tetramer of α1 subunits, and
MAT III, an α1­dimer, are found primarily in liver tissue [210]. They have a medium (Km ≈
100 µM) and low (≈ 1 mM) binding affinity to methionine, respectively [211]. Extrahepatic
tissue, in contrast, hosts primarily MAT II, which is putatively a heterotrimer of two catalytic
α2 and one regulatory β subunit that enable the highest binding affinity to MAT substrates of
all three isoforms (≈ 30µM) [212]. The presence of two isoforms with different Km in liver
points towards a metabolic regulation of MAT gene expression. In fact, a shift in MAT I to
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MAT III ratio has been observed in patients with liver cirrhosis [213]. Furthermore, it has
been found that the regulatory β subunit of MAT II can bind to NADP+ and thus increases
the affinity of the catalytic α2 subunits [214]. In conjunction with the observation that MAT
I/MAT III are inhibited by oxidized glutathione [215], this has sparked the hypothesis that
SAM synthesis is sensitive to the redox state of a cell [210].
SAM is, after ATP, the second most common enzymatic cofactor in cells [191]. The con­
centration of SAM limits the activity of methyltransferases, which stands in contrast to the
highly abundant ATP that saturates kinase sites under physiological conditions [216]. This
highlights the importance of a tightly regulated MAT reaction. SAM is the primary methyl
group donor in cells for about 200 confirmed or predicted methyltransferases [217, 218],
which corresponds to 1­2% of the total cellular proteome [171]. Methylation is the addi­
tion of a CH3 group to a target, which includes a multitude of substrates from DNA, RNA,
protein and metabolites. Although sometimes considered the universal methyl group donor,
some few methylation reactions depend on betaine, choline and folates [219]. Most SAM­
dependent reactions (reaction 3) involve the transfer of methyl groups by methyltransferases,
but several other reaction mechanisms are known [172]. The methionine moiety of SAM can
be decarboxylated by SAM decarboxylase and contribute a propylamine group to polyamine
synthesis. The function of polyamines remains elusive, but they have been associated with
stress conditions and ageing [220]. SAM can also be reductively cleaved into methionine
and an adenosyl radical. The radical is used by a large family of radical SAM enzymes to
perform chemically challenging reactions usually by abstraction of target hydrogens [221]. A
prominent radical SAM reaction is required during lipoic acid synthesis, which is a prosthetic
electron transferring group on PDH, α­ketoglutarate dehydrogenase (KGDH) and others (see
4.4). Radical SAM enzymes are an active field of research with a focus on bacteria; however,
I will mostly discuss methylation reactions below.
4.3 Compartmentalization of methylation reactions
Historically, the interest in methylation took off after the discovery that nuclear DNA methy­
lation modifies gene expression [222, 223], which started the field of epigenetics. It is now
well established that cytosine can be methylated by DNA methyltransferases (DNMTs) on
the 5′­carbon atom yielding 5­methylcytosine (5mC). Although 5mC does not affect Watson­
Crick pairing with guanine, the hypermethylation of repetitive CpN elements mostly induces
DNA compaction and silencing of gene regions [224]. A layer of complexity is added on
top of DNA methylation as tails of histones, the DNA­compacting multimeric proteins, con­
tain numerous PTMs. This includes dynamic methylation on arginine and lysine of various
kinds, but also acetylation, phosphorylation, sumoylation, and others [133]. Epigenetic alter­
ations are one of the hallmarks of cancer cells [225], and several reports have proposed a link
between cellular SAM levels and cancer invasiveness both in vitro and in vivo [226–228].
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Although much focus has been initially put on the (epi­)genetic side of methylation, an
increasing number of marks have been detected throughout the cell on targets with diverse
functions. In the cytosol, mRNAs have been found reversibly methylated on adenine and
a regulatory role on expression control has been proposed [229]. Furthermore, N6,2′­O­
dimethyladenosine in the 5′­mRNA cap has been described to control transcript stability
[230]. Cytosolic ribosomes are heavily methylated both on protein and rRNA components.
Ribosomal proteins are methylated mostly on lysine and arginine residues that are both ex­
posed on the ribosomal surface and hidden in the multimer structure [171]. rRNA methy­
lation is found across all domains of life and at least 13 different types of SAM­dependent
post­transcriptional modifications on all nucleosides are known with a multitude of mapped
methyltransferases [231]. Recent advances in MS techniques led to the detection of 8,030
arginine methylation sites on 3,300 human proteins [180]. These were enriched on compo­
nents of the protein biosynthesis machinery, but also proteins involved in cell cycle and insulin
signaling. Interestingly, these sites have a higher mutation rate compared to unmodified argi­
nine residues across all eukaryotes, but are highly conserved among mammals [180]. The
largest fraction of SAM is required during phosphatidylcholine (PC) synthesis at the endo­
plasmic reticulum [232]. PC is the major lipid component in biological membranes. Deletion
of phosphatidylethanolamine methyltransferase, which is the SAM­dependent enzyme in PC
synthesis, leads to a 50%­decrease in SAH­plasma levels in mice [233], which highlights the
substantial flux of SAM towards synthesis of PC.
Although the primary site of SAM synthesis is in the cytosol, a mitochondrial MATα1
[234] and nuclear­targeted MAT I/III have been described [235] that might meet the elevated
demands of SAM in proliferating cells. Consequently, SAM has to be imported into most
organelles that contain SAM­dependent methyltransferases. It has been proposed that the
Golgi membrane of Caenorhabditis elegans contains a SAM transporter termed SAMT­1.
The nematode Golgi apparatus requires SAM to O­methylate fructose and mannose­residues,
which are extracellularly exposed onmembrane proteins [236]. However, further biochemical
evidence for the SAM­transporting activities of SAMT­1 are still missing. The only conclu­
sive SAM transporter was identified in mitochondria [237], which harbor 30% of cellular
SAM [238]. SAM carrier, S­adenosylmethionine carrier protein (SAMC) or SLC25A26 is a
member of the solute carrier family 25, a group of proteins containing 53 nuclear encoded
mitochondrial transporters in the inner membrane that shuttle a variety of substrates [239].
SLC25A26 is an antiporter for both SAM and SAH [237], which suggests a mechanism how
to resolve the SAH­inhibitory effects on methyltransferases when SAH or homocysteine can­
not be broken down close­by. Three patients with mutations in SLC25A26 are known. De­
pending on the mutation, symptoms ranged from death shortly after birth, acute episodes of
cardiopulmonary failure to progressive muscle weakness [240]. The patient with the most
severe symptoms carried a homozygous splice site mutation and likely did not express a
functional SAM transporter. Patient fibroblasts showed decreased de novo translation and
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a reduction of steady­state levels of OXPHOS subunits. Concentrations of SAM­dependent
metabolites Q­10 and lipoic acid were depressed, which altogether can account for reduced
oxygen consumption in patient cells.
4.4 SAM­dependent modification of mitochondrial components
Known products of SAM­dependent reactions are shown in table 1. The text highlights con­
ceptually relevant targets.
4.4.1 Proteins
Among the 3,030 proteins that were identified with one or more arginine methylation sites
[180], 373 overlapped with Mitocarta [264]. This corresponds to about 25% of all mito­
chondrial proteins and stands in stark contrast to only one biochemically validated arginine
methylation site in the organelle. Five more methylated mitochondrial proteins have been
studied, of which four are methylated on lysine and one on glutamine (Table 1). The com­
plex I subunit NDUFS2, electron transferring flavoprotein (ETF) β (ETF β), and the complex
V subunit ATP synthase subunit c are part of the OXPHOS system. Citrate synthase catalyses
the condensation of acetyl­CoA with oxaloacetate, which is a key regulated reaction of the
TCA cycle. Mitochondrial translation release factor 1L contributes to translation termination
at the mitochondrial ribosome. Finally, the ADP/ATP translocase (ANT) is a major route for
ATP into the cytosol in exchange against ADP. All methyl marks are of regulatory or struc­
tural importance as shown by knock­out of the respective methyltransferase in human cell
lines [134, 242–244, 246], although the directionality of the effect in the case of ANT and
ETF β are unclear [241, 244]. In all five cases, the corresponding methyltransferases local­
izes to mitochondria. For all other proposed methylated proteins in mitochondria it remains
unclear if a polypeptide chain can be methylated in the cytoplasm before being imported.
4.4.2 RNA
Mitochondrial tRNAs are heavily methylated both in stem loops and the anticodon [247]. It is
generally believed that tRNA­base modifications alter the bonding capabilities and contribute
to the stable folding of tRNAs, codon­anticodon recognition and the wobble­characteristics
of certain bases [265]. In contrast to tRNAs, the two mitochondrial ribosomal RNAs are less
abundantly modified with five methylation sites on 12S and four on 16S [266]. Knock­out
of the 12S methyltransferases NSUN4 or TFB1M was embryonic lethal in mice [252, 254]
and it has been shown that almost all methylation marks are relevant for either ribosomal
assembly or function. Among the eleven mitochondrial mRNAs, 20% of ND5 transcripts
were found with a specific 1­methyladenosine site that disrupts base­pairing [259]. However,



























































































































































































































































































































































































































Coenzyme Q requires three mitochondrial methylation reactions on the quinone ring for its
synthesis [267]. Morover, the E2 subunits of four mitochondrial protein complexes use lipoic
acid as a prosthetic group, whose synthesis is SAM dependent: PDH, KGDH, the glycine
cleavage system (GCS), and branched­chain ketoacid dehydrogenase (BCKDH). Lipoyl syn­
thase uses a radical SAM mechanism and abstraction of sulfur atoms from iron­sulfur clus­
ters, which then form part of the oxidized lipoic acid ring [268]. In absence of mitochon­
drial S­adenosylmethionine (mitoSAM) in a patient with non­functional SLC25A26, both
lipoic acid and Q levels were decreased, although not completely abolished [240]. The multi­
enzyme complexes PDH andKGDH catalyse the NADH­gaining decarboxylation of pyruvate
to acetyl­CoA, and α ­ketoglutarate to succinyl­CoA, respectively. The H­protein in the GCS
is lipoylated and contributes to the catabolism of glycine forming ammonia, carbon dioxide
and a one­carbon group that is transferred onto THF [269]. Knock­out of the H­protein in
mice was embryonic lethal [270], which could not be rescued with maternal folate feeding.
Therefore, the authors suggested that the protein could have additional functions besides its
role in the GCS. Lastly, lipoic acid is a prosthetic cofactor on the BCKDH E2 subunit, which
catalyzes decarboxylation of downstream catabolic products of valine, leucine, and isoleucine
[271]. Defects in the BCKDHB gene causes the severe case of maple syrup urine disease type
II [272] characterised by encephalopathy and progressive neurodegeneration.
4.4.4 mtDNA
Several studies report the presence of 5mC on mitochondrial DNA [273]. Methylation of
DNA without regulating transcriptional activity has been detected in a number of inverte­
brates [274]. However, there is evidence that mtDNA methylation correlates with certain
cellular states. An altered methylation pattern in patients with Down syndrome has been re­
ported [275] and exposure to environmental toxins was shown to alter mtDNA methylation
[276]. According to recent data, over­expression of SLC25A26 led to an increased amount
of 5mC on mtDNA in a cancer cell line [277]. The catalysing enzyme is under debate. One
percent of DNA methyltransferase 1 (DNMT1) isoform 1 has been found to localize to mi­
tochondria [278], but recent studies questioned this finding and suggest DNMT1 isoform 3
instead [279]. The effect size has been small in all reported studies with a maximum of 5%
of all cytosines being methylated. The presence of mtDNA methylation has been disputed
in several reports. Olova et al. showed that a standard library preparation including bisulfite
conversion for whole genome methylation screens overestimates the amount of methylated
sites [280]. Moreover, an MS­based method failed to detect 5mC on mtDNA [281]. Notably,
the methylation signal disappears when scaling up the read depth of sequencing and after de­
coiling of mtDNA by restriction enzyme treatment [282], rather suggesting a technical artifact




Mitochondria are not just passive receivers of cellular signals but are major players develop­
ment and homoeostasis. Besides their central role in metabolism, mitochondria contribute to
calcium signaling, regulate stress responses and apoptosis, synthesise iron­sulfur clusters, and
produce the majority of cellular ROS that serve as a pivotal signaling molecule at low doses to
impact kinases, growth factors and transcription factors [283, 284]. During embryogenesis, a
totipotent oocyte divides and initiates differentiation programs that result in a highly complex
multicellular organism in which every niche has characteristic metabolic conditions. These
are determined by, for instance, the niche’s distance to blood, its oxygen partial pressure and
circulatory distance to lungs, and cellular barrier functions between the niche and the primary
nutrient supply, which alter metabolite compositions.
Mitochondria must rapidly adapt to meet the constantly changing metabolic demands
during development. It is well established that experimental inhibition of OXPHOS pre­
vents stem cell differentiation [285, 286]. For instance, oxidative metabolism is required
for lineage commitment during cardiac differentiation of stem cells [287]. Moreover, the
above­discussed mitochondrial route of the one­carbon cycle, and the indirect production of
acetyl­CoA through TCA­cycle derived citrate, are pivotal for establishing and maintaining
the nuclear epigenome in rapidly dividing cells [283].
In addition, a number of findings strengthen the pivotal role of mitochondria during neu­
ronal development. The mammalian brain consists of various cell types that develop during
embryonic and postnatal neuro­ and gliogenesis [288]. The axonal outgrowth depends on bal­
anced mitochondrial fusion and fission, and loss of the fusion­promoting GTPase mitofusin
2 in dopaminergic midbrain neurons caused a loss of striatal projections, depletion of mito­
chondrial ubiquinone and severe locomotor dysfunction in mice [289, 290]. Moreover, the
young brain relies predominately on glycolysis during synapse formation despite abundant
oxygen, termed aerobic glycolysis [291, 292]. Differentiation of single cells in the mouse
neocortex induces an early transcriptional program that is characteristic for mitochondrial in­
volvement [293]. Furthermore, an up­regulation of transcripts encoding OXPHOS subunits
was observed in adult hippocampal neurogenesis [294]. Specifically, complex V was con­
sistently up­regulated during early lineage progression [295], and inhibition of complex I or



























Figure 8: Metabolic changes during neuronal development. Adapted from Maffezzini et al. [291] under the
terms of the Creative Commons Attribution Licence 4.0 (CC BY).
was found to be regulated at hexokinase 2 and lactate dehydrogenase A (LDHA), and loss of
both enzymes characterize the switch to OXPHOS in neuronal progenitor cells in vitro [296]
(Figure 8). Interestingly, the brain regions harboring neuronal stem cell populations during
adulthood remain glycolytic [297], suggesting that glycolysis is relevant for maintenance of
the stem cell niche in both the developing and adult brain.
Impaired neuronal differentiation is associated with a wide array of disease such as Autism
spectrum disorders [298], epilepsy [299], and Alzheimer’s disease [300]. Importantly, in­
born errors of metabolism are linked to irreversible brain injury [301]. In the context of
this thesis, mutations in the gene encoding sequestome 1 (SQSTM1/p62) have been found
in exome sequences of nine patients with suspected mitochondrial dysfunction. The patients
presented with childhood­ or adolescence­onset of neurodegeneration, ataxia and cognitive
decline [302]. p62 is an multifunctional scaffold protein that interplays with, among oth­
ers, KEAP1­Nrf2 signaling during oxidative stress, and LC3­dependent autophagy [303]. In
addition, p62 was found in complex with PINK1 to mediate the selective autophagy of mi­
tochondria, termed mitophagy [304], however, this finding is still controversially debated
[305]. Eleven more patients with similar symptoms have since been reported [306], yet, the
molecular link between defective p62 function and neurodegenerative disease is not clear and
subject to study III.
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6 MITOCHONDRIAL RNA METABOLISM
Mitochondrial genes are transcribed by the DNA­dependent RNA polymerase POLRMT and
auxiliary factors from promoters on both mtDNA strands [307]. This generates polycistronic
transcripts that cover almost the entire genome that are processed by endonucleolytic cleav­
age at tRNA junctions (see Figure 9 for a comprehensive overview). The cloverleaf folding
of tRNAs has been suggested to be essential for recognition of splice sites by the mitochon­
drial endonucleases, RNase P and RNase Z, which is known as the tRNA punctuation model.
However, not all transcripts are flanked by two tRNAs, and the precise mechanisms are not
fully understood.
The released transcripts undergo polyadenylation with about 50 adenines by mitochon­
drial poly(A) polymerase (MTPAP) as part of transcript maturation [308]. In chloroplasts and
bacteria, the polyadenylation of transcripts promotes transcript degradation [309, 310], and
polyadenylation of cytosolic mRNAs in eukaryotes leads to increased mRNA stability and
translational efficiency [71, 311]. In mitochondria, polyadenylation is required to generate
functional stop codons of a number of mitochondrial transcripts, but the exact function of the
poly(A) tail in mitochondria is still unknown [308]. Patients with mutations in MTPAP pre­
sented with spastic ataxia and optic atrophy, indicating an important role for polyadenylation
in mitochondria [312].
A number of key players are relevant for mitochondrial RNA turnover, including polynu­
cleotide phosphorylase (PNPase), SUV3 helicase, leucine­rich pentatricopeptide­repeat con­
taining (LRPPRC) protein and SLIRP [307]. In some organisms, polyadenylation is catalysed
by PNPase, which displays MTPAP activity in vitro and can reversibly catalyse both RNA
degradation and 3′ tail extension [313]. A dual localization of PNPase to both matrix and
intermembrane space of mitochondria has been proposed, where it may regulate mitochon­
drial import of nuclear­encoded RNAs into mitochondria [314]. However, the mechanisms of
mitochondrial RNA import are still not known [315]. Knock­down of SUV3 is pupal lethal
in Dm and causes accumulation of unprocessed transcripts, loss of mature tRNAs and com­
promised OXPHOS activity [316]. This effect was found independent of PNPase, although
there is evidence of a degradosome heterocomplex of SUV3 and PNPase [317].
The RNA­binding proteins LRPPRC and its interaction partner SLIRP are required for
transcript stability and efficient delivery of RNA to the ribosome [318]. A tissue­specific
mousemodel with disrupted LRPPRC expression in heart causedmitochondrial cardiomyopa­








Figure 9: Schematic overview of mitochondrial transcription and translation. Proteins that are relevant
to this thesis work are indicated with filled black circles and the study number they relate to. Reprinted from
D’Souza & Minczuk [307] under the terms of the Creative Commons Attribution Licence 4.0 (CC BY).
tion [319] without affecting tRNAs and rRNAs. Proteomic analyses of mouse hearts showed
loss of complex I, III, IV and V subunits, while complex III and all nuclear­encoded complex
II subunits were unaffected [111]. In humans, mutations in LRPPRC cause a French­Canadian
type of Leigh syndrome with early­onset of mitochondrial disease [320]. Knock­down of the
LRPPRC fly homolog bicoid stability factor (bsf), in study II also called DmLRPPRC1, sim­
ilarly resulted in loss of mitochondrial mRNAs, polyadenylation and subsequent OXPHOS
dysfunction specific to complex I, III and IV [321].
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Everyone has the right freely to participate in the cultural life of the community,
to enjoy the arts and to share in scientific advancement and its benefits.
Universal Declaration of Human Rights, Article 27 (1948)
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7 RESEARCH AIMS
The aim of this thesis work is to adapt and apply tools to map the diversity of mitochondria,
to generate hypotheses on the aetiology of mitochondrial dysfunction, and to build novel
functional networks that are useful in understanding human disease. In study I and II, I want
to shed light on the fine tuning of mitochondrial function by post­translational modifications
(PTMs). The overall set of transcripts and proteins is the interest of study III and IV, in which
we aim to identify the primary cause of mitochondrial dysfunction and arising secondary
consequences by transcriptomics and proteomics.
Methylation is a small protein modification that is essential for epigenetic control of gene
expression in the nucleus, and we are also starting to appreciate its widespread relevance for
cytosolic protein control. At the onset of study I, three patients with mitochondria­specific
depletion of the primary methyl group donor SAM had been reported by Kishita et al. [240].
The symptoms of the three children ranged from repeated episodes of lactic acidosis, car­
diopulmonary complications to death at five days after birth. This highlighted the relevance
of mitochondrial methylation in human pathophysiology. However, the molecular disease­
causingmechanisms were mostly unclear. The aim of study I is to generate patient­specific fly
and mouse models of mitoSAM deficiency by mutating the inner­membrane carrier SAMC,
and to characterize the arising defects with molecular and systems biology techniques. In
addition, the targets of mitoSAM are not well characterized. I will apply a multi­layered
screening strategy to identify methylation sites on mitochondrial proteins (the mitochondrial
methylome) in fly, mouse and human. Combining the methylome with model data, we aim
at pinpointing relevant sites that are supporting mitochondrial function. SAMC is the only
known route for SAM into mitochondria, but considerable residual methylation in a patient
with truncated and likely fully dysfunctional SAMC suggested that other transporters might
exist. We aim at identifying redundancy in mitoSAM import, and exploit these in the design
of future treatment strategies.
The quest to identify the mitochondrial methylome involved SILAC in fruit flies with
heavy methionine, for which three similar technical approaches had been published [81–83].
However, we soon realised the technical shortcomings of previous methods with low labeling
efficiency, undesirable amino acid conversion and astronomical costs. Therefore, I aim at de­
veloping a more suitable and flexible method for SILAC in flies in study II based on a fully
defined holidic food source [322]. I want to technically validate the method and highlight
its power in a difficult­to­solve showcase. Modification of mitochondrial proteins by phos­
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phorylation is under­represented across the cell [169, 170] and requires accurate and highly
sensitive proteomics approaches during sample preparation and MS data acquisition. In a fly
model of mitochondrial dysfunction, I want to identify and quantify mitochondrial protein
phosphorylation sites that are sensitive to an OXPHOS­specific primary defect. This study
will contribute to higher data robustness that is transferable to study I and, importantly, shall
raise attention for the power of proteomics in a marvellous model system in the fly commu­
nity.
Variants in up to 870 genes are known that are linked to metabolic disease, including
mitochondrial dysfunction [33]. In order to identify treatment options, knowledge on the
molecular pathomechanism is important, but in many cases not known, especially for novel
variants. At the start of study III, Haack et al. had reported nine patients with three biallelic
loss­of­function variants in SQSTM1/p62 that presented with slowly progressive neurodegen­
erative disease [302]. p62 is an autophagy adaptor protein with a suggested role in mitophagy.
We want to elucidate the causative link between neurodegeneration and mitochondria upon
loss of p62. In patient­derived NESC, we perform transcriptomics and proteomics to identify
dysregulated functional protein networks and metabolic pathways. This is the first study that
uses a multi­omics approach in our laboratory, and thus the aim is also to benchmark omics
techniques for molecular characterisation of mitochondrial dysfunction.
While the role of individual proteins in mitochondrial RNA metabolism has been studied
in depth, their functional interplay is not well understood. In study IV, we generate individual
and combined mutant fly models with affected SUV3, PNPase, DmLRPPRC1/bsf and PAP
expression, and characterize their involvement in RNA metabolism and the order of events
they act in. Furthermore, by employing antibody­based enrichment and RNA­Seq, we want
to explore the accumulation of stress­related RNA intermediates. This will be of relevance in
diseases that impair mitochondrial RNA turnover, and contribute to a better understanding of
the post­transcriptional events in the organelle.
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8 FURTHER MATERIALS AND METHODS
8.1 Generation of fly models
Gene­specific knock­in Dm lines were generated by ends­out gene targeting [323], replacing
the endogenous locus of CG4743/SAMC with a w+ marker gene and an attP cassette (Figure
10). The attP site was subsequently used to introduce attB­site bearing CG4743­constructs
with patient or non­sense mutations, or a control rescue construct.
8.2 Mitochondrial SAM import assay
Mitochondrial SAM import in Dm was quantified by incubating 50 µg of isolated mitochon­
dria in a suitable buffer containing 1.12 µM radioactively labeled [3H3] SAM for 20 minutes
at 30 ◦C. Mitochondria were then washed in ice­cold assay buffer supplemented with 1 mM
unlabeled SAM, and radioactive decay was quantified on a β­counter.
8.3 Oxygen consumption measurements
Electron transport chain­dependent respiration was quantified in disrupted Dm larvae using
an Oxygraph­2K respirometer (Oroboros). Samples in respiratory buffer were permeabilizied
with digitonin. Complex I­dependent respiration was quantified with pyruvate, glutamate,
malate and ADP. Complex I+II­dependent respiration was quantified after addition of succi­
nate, and complex II­dependent oxygen consumption was derived after addition of the com­
plex I inhibitor rotenone. The non­mitochondrial background was determined after addition
of antimycin A. Lastly, complex IV activity was measured after addition of tetramethyl­p­
phenylenediamine (TMPD) and ascorbate, followed by shutdown of the system with potas­
sium cyanide.
8.4 Bisulfite pyrosequencing
Mitochondrial 12S ribosomal RNAhas twomethylationmarks on cytosines at murine position
909 and 911. An assay has been developed to quantify the site­specific occupancy in fly
and mouse by low­throughput sequencing. Purified and DNase­treated RNA was bisulfite­


































































































































was chosen that annealed next to the two sites of interest, and the sequence was read by
pyrosequencing. The occupancy was expressed as modified over total signal at the two sites.
8.5 SILAF and methyl­SILAF
Stable isotope labeling of amino acids in flies (SILAF) was developed and performed as de­
scribed [324, 325]. In brief, the unlabeled amino acids lysine, serine and methionine of a
holidic food source for Dm [326, 327] were changed to equimolar amounts of L­lysine­[13C6,
15N0], L­serine­[13C,15N,2,2,3­2H3] and L­methionine­[methyl­13C2H3]. Parental flies were
kept on the holidic food source for 8 h to lay eggs. Experiments were performed on seven
or eight day­old F1 larvae, or on hatched flies. Peptides were prepared by Lys­C or tryptic
digest for lysine or methionine labeled proteins, respectively.
8.6 Bioinformatic data analysis
8.6.1 Proteomics
Quality control of raw files was performed with RawMeat (Vast Scientific). Computations
were performed on a local machine or on resources provided by Swedish National Infrastruc­
ture for Computing (SNIC) through Uppsala Multidisciplinary Center for Advanced Com­
putational Science (UPPMAX) under project SNIC 2019­8­175 and uppstore2018188. For
label­free quantifications, Quandenser was used at standard settings [328] on the cluster. To
identify methylation sites in methyl­SILAF data, MaxQuant [156] was set up on the clus­
ter. Light and heavy methyl groups were identified in separate runs, and a confidence score
was calculated with [184]. The incorporation rates of labeled amino acids was assessed lo­
cally with MaxQuant [156] in a dual­labeling experiment, and the ratio of heavy­to­light pep­
tide intensity for methionine labeling and heavy­to­light protein intensity for lysine labeling
was calculated as a proxy for label incorporation rates. The phosphoproteomes on lysine­
labeled SILAF samples were quantified on a local machine with MaxQuant [156] in dual
label model with phosphorylation as a variable modification. Spectra from tandem mass tag
(TMT)­labeled peptides were mapped locally with MaxQuant [156] by manual configuration
of reporter ions and batch­dependent correction factors.
All subsequent analysis was performed in R that was run in an R Studio environment or
through console scripts. Differential expression proteomics used a limma moderated t test
[329] and FDR­adjusted p values.
8.6.2 RNA­Seq
The 75 base pair (bp) paired­end sequences were quasi­mapped against a cDNA library with
Salmon [330] and differential expression was calculated with DESeq2 [331] including p value
adjustment by independent hypothesis weighing [332]. Double­stranded RNAwas quantified
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after J2 anti­double stranded RNA antibody­based enrichment following a previously estab­
lished protocol [333]. 42 bp paired­end sequence reads were mapped against a whole­genome
library with Bowtie 2 [334], converted and indexed with Samtools 2 [335] and visualised in
IGV viewer [336].
8.7 Ethical considerations
Three of four studies involve a basic molecular characterisation of genetically modified fruit
flies with the intention of mimicking the disease status of human patients. In study I, the fly
data was subsequently validated in a mouse model. Morally, several layers of complexity
arise: (1) terminating the life of a large number of fruit flies, (2) modifying fruit fly genomes,
(3) mimicking disorders of alive patients in flies, (4) breeding and terminating the life of mice
and (5) using public financial resources to understand the disease mechanism of three known
affected individuals instead of funding research on widespread diseases.
Fruit flies are a collection of cells that propagate themselves, react to environmental stim­
uli including stress, and are able to intermittently keep the fine balance between order and
chaos, called life. This description fits to humans, mice, flies and yeast cells alike. Doing re­
search strictly following Kant’s categorical imperative would put us into trouble as we would
not be allowed to distinguish between any life form and could neither use mice nor cell culture
in our work. Yet, our cultural imprinting on moral standards would make us draw a rectangle
around flies and yeast cells that we label with ”acceptable to kill”. It has been argued that the
less empathy we feel with an individual, be it human or not, the more acceptable it is to do
harm to it. It is scientifically almost impossible to prove or disprove conciousness in flies,
which sets them far apart from humans in our perspective. I follow this common perception
here, but lacking a truly substantial ethical argument scientists shall take special care not to
make the insects suffer unnecessarily and to treat them with respect. On top of this, under­
standing the nature as a whole is a driving force that sets certain animals apart from others due
to natural neuronal constraints. Doing so, the physical environment including wild living flies
can benefit from my activities and I think Homo sapiens can regard it as their responsibility
to protect the planet Earth. That this is blunt theory and not happening in reality is part of
another discussion. However, along this line, modifying a fruit fly genome contributes to a
general understanding of the world as long as these flies stay contained and do not lead to a
shift of the genetic pool of a wild living population.
Following these arguments, it is irrelevant from a fly perspective if the mutation is derived
from a patient or not. However, a patient might suffer from the idea that her or his disease
is mimicked in fruit flies, which could lead to the perception that the patient is similar to a
fly. Yet, it might be a comforting thought for a sick person that researchers invest their life
time and public money into finding a molecular disease mechanism. More utilitaristic, the
molecular explanation is ultimately a basis for treatment and although we are not able to treat
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most monogenic diseases today, my work will help patients on a long run to lead a normal
life, that is without permanent medical assistance.
Applying the moral reasoning that the life of a fly can be sacrificed for the good of human
kind and beyond, is clearly more difficult to apply to mice with our cultural perception in
mind. It is easier to find empathy with a mouse than with a fly. On the positive side, study I
uses first fruit flies to identify relevant diseasemechanisms and continues with amore targeted
strategy to mice. Doing that, we cut down the number of animals. Yet, are we allowed to kill
and genetically modify those that remain? As before, it has to be made sure that mice do
not suffer unnecessarily from our actions, which requires thorough planning. Additionally to
that, I personally do rate the life of human beings higher. I am comforting myself with the
thought that 2000 years of natural philosophical history wouldn’t have been so controversial
if a clear­cut threshold between ”acceptable” and ”unacceptable to kill” would exist.
Lastly, the research we are doing is without doubt costly, however, biomedical research
in the last 150 years has majorly contributed to the reduction of human suffering all across the
globe. If our moral maxim is to contribute to every humans well­being, responsible biomed­
ical research is fully acceptable. I think this is true irrespective of the number of people the
research is targeted at. Our study design originated from the pathologies of three patients. Yet,
we think that the outcome has implications for cancer and ageing. The broader outcomes for
any research study are hard to predict a priori, but understanding the principles of cell biology
and a solid ground of knowledge is inevitably required to ultimately cure human diseases.
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The sycamore fig cannot ripen unless it is scraped;
but they scrape it with iron claws; the fruits thus scraped ripen in four days.
The first known documentation of a S­adenosylmethionine dependent process
by Theóphrastos (c. 371 – c. 287 BC), Enquiry into Plants, book IV
English translation by Sir Arthur Hort
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9 RESULTS AND DISCUSSION
9.1 Paper I: The One­Carbon Pool Controls Mitochondrial En­
ergy Metabolism via Complex I and Iron­Sulfur Clusters
The cytosolicmethionine cycle produces themethyl group donor SAM,which
is then distributed throughout the cell. In mitochondria, SAM enters the ma­
trix via the solute carrier protein SLC25A26/SAMC and is a known cofactor
during RNA and protein methylation and metabolite synthesis. However, the
severe symptoms of patients with mutations in SAMC suggest that our understanding of mi­
toSAM­dependent modifications are incomplete.
Therefore, we modeled mitoSAM deficiency by replacing the endogenous SAMC with
three patient­specific SAMC variants (a123v, i172g, p223l), a non­sense mutated null and
a control rescue construct in Dm. In the fly, the gene CG4743 is the ortholog of human
SLC25A26/SAMC, and we confirmed the mitochondrial localization of C4743 by immunoflu­
orescence microscopy. All patient mutant and null variants caused decreased import of SAM
into mitochondria, but only the p223l and null mutants showed a severe larval­lethal pheno­
type with developmental arrest at an early stage. We observed loss of the SAM­dependent
metabolite lipoic acid. Moreover, markedly reduced ubiquinone­9 levels correlated with a
coupled respiratory chain defect of complex I to III and complex II to III, without affecting iso­
lated complex activities. Transcriptomics and proteomics revealed a prominent up­regulation
of enzymes related to lipoic acid, ubiquinone­9 and iron­sulfur cluster synthesis.
We confirmed the findings in Dm in a mouse model. Homozygous knock­out of SAMC
is embryonic lethal, thus we obtained MEF cells from mouse embryos, which we were able
to grow in cell culture. Similarly, we observed a complete loss of lipoic acid levels, strongly
impaired oxidative phosphorylation, and additionally loss of assembled complex I, III, IV
and V. Methylation of two 12S ribosomal RNA methylation marks were completely absent,
arguing that no redundant mechanisms for SAM import into mitochondria exist in mouse.
Interestingly, the loss of lipoic acid caused stalling of the oxidative TCA cycle and accumu­
lation of α­ketoglutarate. Reassuringly, deep labeling data was compatible with the reductive
carboxylation of glutamine­derived α­ketoglutarate as seen by others [337, 338].
We then asked what the protein targets of mitoSAM are. We employed aMS­basedmethy­
lation screening in Dm with methyl­SILAF labeling that was specifically developed for this
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Figure 11: Graphical summary of paper I.
richment of methylated peptides and offline fractionation. We mapped 216 high­confidence
methyl groups on 205 mitochondrial proteins, without enrichment of a particular functional
category. By medium­scale targeted proteomics, we confirmed 20 and 24 sites in human and
mouse samples, respectively. Most of these sites have not been described previously, and
several positions have been found mutated in patients with mitochondrial disease including
arginine 20 in the complex IV subunit COX6B1 [339] and arginine 72 [340] in the cysteine
desulfurase NFS1 (both human protein positions).
We then asked whether methyl groups would be lost in our models of mitoSAM defi­
ciency. While we did not observe any decrease in fly samples, two site­specific signals were
lost in MEF cell samples while the majority did not change. This suggests that modification
of mitochondrial proteins can happen prior to import and is consistent with previous large­
scale data [136, 341]. We combined the fly model omics data and the methylome library to
pinpoint methyl groups with a potential biological function, and identified a methyl mark on
the clinically relevant arginine 72 of NFS1. When we mutated this site in a human cancer cell
line, the integration of NFS1 into functional heterocomplexes was impaired. It is currently
unclear whether the methylation of NFS1 happens inside of mitochondria, and peptide cleav­
age patterns limited our experimental approach. When ageing a i172g SAMC fly mutant, we
46
observed decreased lifespan, compensatory up­regulation of serine biosynthesis and a specific
loss of complex I subunits. Using data of the Cancer Dependency map, we found a prominent
correlation between gene essentiality of SAMC and the complex I subunit NDUFS2, which
also lost its methyl mark in SAMC knock­out MEF cells. Yet, we failed to observe a signif­
icant reduction in complex I activity, which might be related to the sensitivity of the applied
methods.
Finally, we tested the efficiency of a number of metabolites in rescuing larval lethality.
We identified that both methionine and SAM could elevate cytosolic SAM levels and in part
restore depletion of mitoSAM. Notably, this could partially rescue the larval growth defect,
which can be of clinical importance. Furthermore, we could show that SAMC protein lev­
els do not regulate mitoSAM concentration, contradicting reports on increased mitochondrial
DNAmethylation upon over­expression of SAMC [277]. We thus conclude that the cytosolic
production of SAM downstream of the one­carbon cycle directly translates into mitoSAM
levels and controls mitochondrial function through complex I and iron­sulfur cluster biosyn­
thesis. Dysregulated one­carbon cycle has been linked to various diseases, most notably tumor
development through SAM­dependent epigenetic imbalance [202, 342, 343]. This highlights
the relevance of our findings not only in the pathophysiology of mitochondrial disease, but
also in cancer and ageing­related disorders.
9.2 Paper II: Stable Isotope Labeling of AminoAcids in Flies (SILAF)
Reveals Differential Phosphorylation of Mitochondrial Pro­
teins Upon Loss of OXPHOS Subunits
Tomap the high­confidencemethylome in study I bymethyl­SILAC, wewere
in need for a robust stable isotope­labeling technique in Dm. Adaptations of
SILAC to Dm husbandry practices exist [169, 170] in which labeled yeast is
fed to flies. However, the indirectmethods suffer from undesirable amino acid
conversion and low labeling efficiencies of at most 97.6% just above the threshold of SILAC
usability. To this, high prospective costs limited their adaptation by the fly community.
In paper II, we describe the methodological development of a direct labeling technique for
fruit flies that is highly efficient, flexible and cost effective. We use a previously described
holidic food source [322, 344] that is composed of 47 defined and purified chemicals, in­
cluding eight essential amino acids. Initially, we followed a classical SILAC approach and
exchanged both ”light” lysine­[13C0] and arginine­[15N013C0] against ”heavy” stable­isotope
labeled lysine­[13C6] and arginine­[15N413C6] with subsequent tryptic digestion. We observed
a profound conversion of heavy arginine into proline and thus a loss of MS­signal from heavy
peptides and compromised identification rates. Henceforth, we switched to lysine­[13C6]­
labeling only with endoproteinase Lys­C digestion. This normalized light and heavy peptide
identification and did not perform worse than comparable light tryptic digests. We termed the
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SILAF recipe
  47 ingredients
  Lysine-0 or Lysine-6
  Protein digest with Lys-C
>99% heavy lysine
incorporation in
larvae at day 6
Mitochondrial phosphoproteomics














Figure 12: Graphical summary of paper II [324].
method SILAF and found it slightly more reproducible than label­free quantification.
The labeling efficiency reachedmore than 99.5% at larval stage 2 when larvae were grown
from egg laying on labeled food, thus outcompeting all previous methods. Heavy amino acids
were also incorporated when unlabeled flies were put onto SILAF food, albeit at a much lower
rate reaching at most 45.0% after two labeling weeks. Interestingly, we could use this pulse­
SILAF approach to monitor protein turnover in functional protein categories and found that
ribosomal components were turned over much faster than OXPHOS subunits in adult flies.
SILAC can reduce variabilities introduced during sample preparation by combining a light
and heavy fraction early on in the preparation process. SILAC is therefore especially pow­
erful for analysis pipelines that demand pre­MS offline fractionation. We thus tested SILAF
on mixes of male and female flies and performed small­scale peptide fractionation. We ob­
served high correlation between replicates and biologically meaningful differential expression
that reproduced previously published yeast­based SILAC experiments [81]. We then asked
whether we could quantify phosphorylation site occupancy and chose to compare yeast­food
to holidic­food grown flies. SILAF combined with high pH reversed phase liquid chromatog­
raphy and LC­MS/MS quantified 5,038 proteins and identified 14,008 phosphorylation sites,
of which 1,523 occupancies were quantified. We found up­regulation of enzymes related to
gluconeogenesis, glycogen degradation and the ribosome, and down­regulation of glycolysis
and OXPHOS proteins, suggesting increased energetic usage of amino acids.
Finally, we applied SILAF to a fly model of mitochondrial disease. We knocked down
bsf/DmLRPPRC1, which is involved in mitochondrial protein biosynthesis by stabilizing
mRNA transcripts. DmLRPPRC1 loss caused an almost exclusive reduction of OXPHOS
components, which is consistent with previous molecular data in that model [71]. We mapped
the protein phosphorylation landscape in enriched mitochondrial samples, and found that pro­
tein phosphorylation sites are under­represented in the mitochondrial compartment compared
to the whole cell. This is in agreement with reports in mouse and human [169, 170].
Among the differentially phosphorylated sites upon DmLRPPRC1 knock­down, we con­
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firmed previously known regulatory marks and found two novel sites on the complex I subunit
NDUFB10 (tyrosine 126) and the complex IV subunit NDUFA4 (serine 66) with a significant
stoichiometric increase. Both amino acids are conserved to human and the phospho­groups
have been detected in previous large­scale reports, but not linked to a biological function.
Tyrosine 126 of NDUFB10 anchors the protein into ND4 in complex I, and absence of a
cryogenic electron microscopy trace at the complex I site suggested that only the free, but
not the incorporated subunit is phosphorylated. We mutated serine 66 of NDUFA4 to the
non­phosphorylatable serine mimetic alanine in a human cancer cell line and observed less
association of the mutated protein with intact complex IV on native gel electrophoresis. This
argues that phospho­serine 66 might be required for binding of NDUFA4 to complex IV. Of
note, it has been proposed that NDUFA4­binding prevents dimerization of complex IV and
thus might impact supercomplex formation [345]. However, the initial screening requires
additional and extensive molecular follow­up studies to underpin the structural relevance of
both phospho­sites.
We conclude that SILAF is a highly powerful technique for label­based fly proteomics
with almost complete labeling at a fraction of previous costs. In fact, one milligram of fully
labeled complex peptides can be obtained for less than $15. In an additional methods paper,
we provide a simple­to­follow recipe with notes [325] and we hope that the fly community
uses this opportunity to perform more proteomics studies on fly models.
9.3 Paper III: SQSTM1/p62­Directed Metabolic Reprogramming
Is Essential for Normal Neurodifferentiation
Haack et al. reported nine individuals with biallelic loss­of­function variants
in the autophagy receptor protein SQSTM1/p62 [302]. The suggested role
of p62 in removal of damaged mitochondria led us study the link between
loss of p62 in patients and compromised mitochondrial function. Due to the
strict neurodegenerative clinical symptoms, we obtained NESC from two patient fibroblast
lines. Loss of p62 severely compromised differentiation into mature neurons in patient and
CRISPR/Cas9 knock­out NESC lines.
Assessment ofmitochondrial function showed amild reduction of complex I activity while
ATP productionwas normal. However, we observed increased sensitivity to the protonophores
carbonyl cyanide m­chlorophenyl hydrazone (CCCP) and 2,4­dinitrophenol (DNP). Basal
levels of ROS in NESC were normal, but were significantly increased upon induction of
differentiation in patient lines alongside reduced levels of transcripts related to glutathione
metabolism. Treatment with the antioxidant N­acetyl cysteine (NAC) could in part rescue
the defect. Components of the KEAP1­Nrf1 signaling pathway were unchanged in mutant
cells, which suggests that p62 acts independent of this relay during oxidative stress. Of note,
mitochondrial clearance upon stress was not affected by loss of p62.
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Figure 13: Graphical summary of paper III.
Reprinted from Jalvo­Garrido et al. [346] under the
terms of the Creative Commons Attribution BY­ND Li­
cence 4.0.
We performed transcriptomics and pro­
teomics in resting NESC and at four days
after initiation of differentiation. Func­
tional pathway analysis confirmed the on­
set of neuronal differentiation in controls,
but a much less pronounced transcriptional
response in knock­out cells. Furthermore,
proteins of the OXPHOS system were read­
ily increasing in knock­outs, while this well­
known signature of neuronal development
was absent in mutant cells. We found a
prominent accumulation of LDHA due to
loss of p62 at resting state, and disturbed
pyruvate metabolism. Reduction of LDHA
expression is a hallmark of neuronal stem
cell differentiation [296] and the initial ab­
normally high levels of LDHA in p62 knock­out cells might explain the failure to differentiate,
although LDHA was normal in patient fibroblasts.
Our data finds support in a recent report that describes increased lactate levels in cere­
brospinal fluid of patients with dysfunctional p62. The same study generated a zebrafish
model, in which loss of p62 led to structural abnormalities in hippocampus [306]. Thus, we
suggest that progressive neurodegeneration in patients with loss of p62 is caused by a failure
to switch from a pro­glycolytic signature to oxidative phosphorylation during differentiation
of neuronal stem cells.
9.4 Paper IV: Defects of mitochondrial RNA turnover lead to the
accumulation of double­stranded RNA in vivo
Mitochondrial RNA turnover is regulated by a set of enzymes, including PN­
Pase and SUV3 that form the degradosome complex, MTPAP and LRPPRC.
How they interact in vivo is incompletely understood. In this study, we char­
acterize the function of DmPNPase, and combine this fly model with knock­
down, knock­out or over­expression lines of the other factors. CRISPR/Cas9­induced knock­
out of the PNPase fly homolog CG11337 caused larval lethality. We found reduction of iso­
lated and coupled OXPHOS activity together with accumulation of mitochondrial mRNAs
and loss of specific tRNAs. PNPase and SUV3 acted synergistically on mitochondrial mR­
NAs, as concomitant knock­down had additive effects on mRNA accumulation. Similarly,
knock­out of MTPAP caused loss of polyadenylation and accumulation of mitochondrial mR­







































Figure 14: Graphical summary of paper IV. Solving the puzzle of mitochondrial RNA metabolism. Adapted
from Pajak et al. [347] under the terms of the Creative Commons Attribution Licence 4.0 (CC BY).
polyA­tail on mitochondrial transcripts has neither an exclusively protective role nor signals
degradation. Knock­down of LRPPRC reduced mRNA abundance, as has been described
in Dm before [71], and this was reversed by simultaneous knock­down of either PNPase or
SUV3, indicating that LRPPRC is in fact required to protect mitochondrial mRNAs from
degradation by the degradosome complex.
Both strands of mtDNA are transcribed from dedicated promoters into polycistronic RNA
transcripts that are processed to mature transcripts. This causes the formation of antisense
RNA species that are rapidly degraded under physiological conditions [348]. We found ac­
cumulation of double­stranded RNA by immunofluorescence microscopy when PNPase or
MTPAP was lost, and these transcripts preferentially localized to the cytosol. This was con­
firmed by antibody­based enrichment of double stranded RNA and subsequent RNA sequenc­
ing [333]. This indicates that mitochondrial RNA can be released into the cytosol, and that
disruption of mitochondrial RNA metabolism causes accumulation of double­stranded tran­
scripts. In a human cell line, mitochondrial release of double­stranded RNA activates an
MDA5­driven antiviral response [333]. Although this pathway is not conserved in flies, we
did observe down­regulation of antiviral response genes upon loss of any of the herein studied
proteins, suggesting increased sensitivity to infections of these models. Whether this trans­
lates into measurable pathological consequences during immune surveillance is still unclear.
However, immunological failure upon mitochondrial dysfunction is currently an active area
of research [349], and our findings can contribute to the question why some patients with
mitochondrial dysfunction are more prone to infection [350].
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10 CONCLUSIONS AND PERSPECTIVES
Accurate quantification of thousands of transcripts and proteins within hours ­ it is difficult
for a molecular biologist to dismiss the appeal. In this thesis work, I made large­scale data
compatible with molecular findings and developed new methods to unravel the complexity of
mitochondrial function in health and disease. This gives an exciting new perspective on the
intricate and complex function of this organelle, and offers a roadmap for arising and urgent
questions on mitochondrial dysfunction.
We zoomed into post­translational modifications on mitochondrial proteins, and by com­
bining powerful proteomics techniques with genetic models we mapped the mitochondrial
protein methylome in the three species fly, mouse and human. While we were able to follow
up on just two methylation sites, two hundred more remain to be studied that do not have an
annotated biological function. We were surprised to find most proteins methylated outside
of the organelle, and it will be highly interesting to understand the molecular machinery that
is able to modify polypeptide chains prior to import. We propose that mitochondria are re­
sponsive to one­carbon cycle activity and cytosolic SAM production rates, comparable to the
epigenome and SAM­dependent metabolite synthesis as shown by others. We can partially
rescue the growth defect of a fly with compromised SAM import into mitochondria and the
great hope is that this can benefit sick children and adults with SAMC variants. Moreover,
with the growing body of literature on the one­carbon cycle in cancer metabolism and ageing,
our results can be of wide impact outside of the mitochondrial field.
The fruit fly is an extremely powerful model system, and thousands of lines are publicly
available at stock centres. This, in combination with their controlled genetic background
makes the fly ideal for omics­driven research. Some tools are readily available for this, while
others are missing. We developed SILAF, a versatile and efficient labeling technique for pro­
teomic studies onDrosophila. While SILAF was highly useful for our PTM screens, we hope
that the method excites researchers in theDrosophila community to exploit proteomics more.
The true power of systems biology can only unfold with a sufficient number of datasets that
are made publicly accessible along with assiduous documentation of the acquisition process.
To bring fly studies up to speed, gene nomenclatures need to be updated to make large­scale
datasets better understandable and comparable to other species. Approximately 75%of human
disease causing genes are conserved in Dm [351]. However, the dominance of the system­
atic but vacuous CG nomenclature can make it hard for non­Drosophilists to appreciate the
enormous potential of this model system.
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I witnessed several times that molecular biologists see the dawn of systems biology as
a threat to wet­lab based experiments, and I got asked whether it might be good investment
to start learning programming now. I certainly got excited about the idea that we can get a
deeper understanding of real biologywith digital networkmodels. However, I thinkmolecular
biology will continue to be an important backbone of biomedical research. For instance, study
IV combines various genetic models to understand causality within the mitochondrial RNA
degradation pathway. I encourage the reader to have a detailed look at this beautiful paper that
I was very happy to have contributed to. The proposed mechanisms were logically deductible
only by using genetics, and currently I cannot see how an omics study could have come to the
same conclusions.
Figure 15: A correlation of fold changes over 100 pro­
teomic datasets, projected onto the mitochondrial ribo­
some. Dark yellow: MRPL52; shades of blue: correla­
tion rank with MRPL52 levels.
Molecular biology is very powerful
when a small set of proteins are under inves­
tigation. On a larger systems scale, though,
the human mind is limited in understand­
ing complex interactions and networks with
thousands of nodes. Systems biology can
assist in delineating hypotheses on disease­
causingmechanisms, and wewill have an in­
creasingly comprehensive understanding of
the cell with more datasets. At the Divi­
sion of Molecular Metabolism at Karolin­
ska Institute, Oleksandr Lytovchenko and
I have been collecting more than 100 pro­
cessed proteomic datasets from mouse mod­
els and human cell lines with mitochondrial
dysfunction [352]. We are starting to see exciting patterns already with the little data we have
(Figure 15). The current limit of systems biology is data interpretation and most data points
in large­scale studies remain unexplored when they are not of interest for supporting the cen­
tral hypothesis. Thus, it will require both skilled programmers who make machine learning
tools accessible to non­computer scientists, and knowledgeable molecular biologists with bi­
ological insight to push these limits of data interpretation. Systems biology is a novel era of
bioscience that will be increasingly interdisciplinary, challenging, and fun.
53
Claude Debussy, Doctor Gradus ad Parnassum (1908)
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